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 Endosomes and lysosomes (endolysosomes) are acidic organelles that 
are important both physiologically and pathologically. Implicated in the 
physiological and pathophysiological processes regulated by endolysosomes are 
readily releasable stores of cations including ferrous iron (Fe2+); an essential 
cofactor for the generation of reactive oxygen species (ROS). In determining the 
extent to which and mechanisms by which Fe2+ released from endolysosomes 
affects cellular functions it was important to determine levels of Fe2+ in 
endolysosomes. In some cells and by other researchers, FeRhoNox-1 was found 
to detect Fe2+ in acidic organelles known as Golgi. Here, using U87MG 
astrocytoma cells and primary cultures of rat neurons we report that FeRhoNox-1 
is highly specific for Fe2+, that FeRhoNox-1 positive stores are largely localized in 
endolysosomes and not in Golgi, that control levels of Fe2+ were 36.3 ± 13.6 µM 
in endolysosomes, and that the stores of Fe2+ in endolysosomes increased to  
75 ± 15.7 µM when cells were incubated with ferric ammonium citrate and 
decreased to 0.08 ± 0.05 µM when cells were incubated with the iron chelator 
deferoxamine. Furthermore, subpopulations of endolysosomes exist with 
extensive variability in Fe2+ content. Our findings demonstrate the utility of using 
FeRhoNox-1 to measure Fe2+ stores in endolysosomes and suggest that this 
probe will find important uses in better understanding cellular events downstream 
of released endolysosome Fe2+. 
xvii 
 Mitochondria are subject to iron overload under a variety of conditions and 
disease states, but it is not clear what are the subcellular origins of this iron nor 
its consequences. Endolysosomes are storage sites of ferrous iron (Fe2+), and 
the degree to which and the precise mechanisms by which endolysosome Fe2+ 
contribute to iron-dependent changes to mitochondria and cell injury remains 
uncertain. Here, our studies were aimed to determine the role of inter-organellar 
signaling of Fe2+ from iron-rich endolysosomes to mitochondria under 
pharmacologically-induced conditions. We demonstrated, in U87MG astrocytoma 
cells, mouse primary hepatocytes, and primary cultures of rat cortical neurons, 
that Fe2+ within endolysosomes was translocated to the mitochondria resulting in 
mitochondrial dysfunction and cell death. The weak-base chloroquine and the 
vacuolar-ATPase inhibitor bafilomycin A1 both de-acidify endolysosomes and 
both induced the release of Fe2+ and this resulted in increased concentrations of 
Fe2+ in the cytoplasm and in mitochondria. Furthermore, the endocytosed iron 
chelator, deferoxamine, inhibited the release of bafilomycin A1- and chloroquine-
induced release of endolysosome stores of Fe2+ and prevented the induced 
increases of ROS in cytoplasm and mitochondria. These findings demonstrate 
that redox-active Fe2+ in endolysosomes plays a key upstream role in 
mitochondrial iron accumulation and dysfunction, and deferoxamine might be 
potential adjunctive therapeutic strategies in preventing neurotoxicity and 
enhancing therapeutic outcomes of disease.  
 Drugs of abuse including the opioid morphine increase levels of reactive 
oxygen species (ROS) and predispose cells to insult-induced cell death. 
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However, it remains uncertain as to the underlying mechanisms. Iron has long 
been known to be required for the generation of mitochondrial ROS and 
endolysosomes are major storage sites of ferrous iron (Fe2+).  Yet, the degree to 
which and the precise mechanisms by which endolysosome iron plays a role in 
mitochondrial dysfunction remains uncertain. Here, our studies were aimed to 
determine the effects of morphine on inter-organellar signaling of Fe2+ from iron-
rich endolysosomes to mitochondria. We demonstrated, in U87MG astrocytoma 
cells, that endolysosome Fe2+ is translocated to mitochondria and results in 
mitochondrial dysfunction. Morphine de-acidification of endolysosomes caused 
the release of Fe2+ from endolysosomes and increased levels of Fe2+ in cytosol 
and in. The morphine-induced effects on endolysosome Fe2+ appeared to be 
regulated through mu opioid receptors because naloxone blocked the de-
acidification of endolysosomes by morphine and the release of endolysosome 
iron. Furthermore, the endocytosed iron chelator, deferoxamine, inhibited the 
release of redox-active Fe2+ into the cytosol and the morphine-induced increases 
in mitochondrial ROS. These findings demonstrate that redox-active Fe2+ in 
endolysosomes plays a key upstream role in mitochondrial dysfunction, and 
deferoxamine might be a potentially useful therapeutic strategy associated with 
opioid use disorders.   
 HIV-associated neurocognitive disorder (HAND) affects 50% of people 
living with HIV-1 despite viral suppression achieved by antiretroviral therapies. 
Pathologically, brain tissue from HAND patients has shown morphological 
changes to intracellular organelles including endolysosomes and mitochondria. 
xix 
Moreover, people living with HIV-1 show elevated iron serum levels and iron 
chelators have been suggested as an adjuvant therapy to antiretroviral 
therapeutics. Mechanistically, soluble factors including the HIV-1 coat protein 
gp120 have been implicated in HAND pathogenesis. Here, we tested the 
hypothesis that HIV-1 gp120-induced de-acidification of endolysosomes leads to 
an efflux of iron from endolysosomes and a subsequent increase in levels of 
cytosolic and mitochondrial reactive oxygen species (ROS). We used U87MG 
glioblastoma cells and time-lapse confocal microscopy to measure gp120-
induced changes in endolysosome pH, endolysosome iron, cytosolic and 
mitochondrial iron, and ROS levels. HIV-1 gp120 de-acidified endolysosomes, 
reduced endolysosome iron levels, increased levels of cytosolic and 
mitochondrial iron, and increased levels of cytosolic and mitochondrial ROS. 
These effects were all attenuated significantly by the iron chelator deferoxamine 
that only enters cells via endocytosis. These results suggest that cellular and 
subcellular effects of HIV-1 gp120 can be downstream of its ability to de-acidify 
endolysosomes and increase the release of iron from endolysosomes. Thus, 
endolysosomes might represent an early and upstream target for therapeutic 





Endosomes and Lysosomes 
 The discovery and functional significance of endosomes and lysosomes 
were honored with Nobel prizes for lysosomes in 1955 by Christian de Duve (de 
Duve, 2005) and for endosomes and endocytosis in 1985 (Motulsky, 1986). 
Endosomes are membrane-bound compartments involved in the endocytic 
transport pathway, and molecules or ligands internalized from the plasma 
membrane follow this pathway to lysosomes for degradation. Alternatively, 
endocytosed materials and endosomes themselves can be recycled back to the 
plasma membrane from which they can release their contents extracellularly 
(Stoorvogel et al., 1991). The endomembrane system includes endosomes, 
lysosomes, the Golgi apparatus, endoplasmic reticulum, nuclear membranes; 
endosomes are known as sorting compartments of this system (Mellman, 1996). 
Endosomes are classified as early, sorting, or late, and as endosomes mature 
their lumen becomes more acidic where, eventually, they fuse with lysosomes as 
shown in Figure 1.1 (Futter et al., 1996, Luzio et al., 2000, Lafourcade et al., 
2008). This transition from late endosomes to lysosomes is unidirectional since 




Figure 1. 1.  The endolysosomal pathway: Schematic diagram showing early 
endosomes maturing into lysosomes. Also, the autophagy 
process is followed by fusion of autophagosomes either with 
lysosomes to form autophagosomes, or to late endosomes in 
which amphisomes fuse with lysosomes to form autolysosomes. 
(Cited from Hansen, T. BMC Biology (2011)). 
molecules in the lumen of endosomes transition into lysosomes. Because 
endosomes fuse with lysosomes as a part of the endomembrane pathway and 
the two are not distinguished in this study, the term “endolysosomes” will be used 
hereafter.  
 Endolysosomes have many key physiological functions including plasma 
membrane repair, cell homeostasis, energy metabolism, signal transduction, and 
immune responses (Settembre et al., 2013, Perera and Zoncu, 2016). The main 
function of endolysosomes is to process molecules taken in by cells and to 
recycle damaged cellular components, both of which are conducted by the 
hydrolytic enzymes within the lumen of endolysosomes (Perera and Zoncu, 
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2016). A defining feature of endolysosomes is their acidic internal pH, which 
ranges from 4.5 to 5.5. The acidic nature of endolysosomes is established and 
maintained by vacuolar H+ ATPase (v-ATPase) that pumps protons into the 
lumen of endolysosomes in conjunction with counterflux of other ion species 
such as Cl-, Na+, and K+ through membrane channels (Forgac, 2007, Ishida 
et al., 2013, Mindell, 2012B). The acidic luminal pH of endolysosomes provides 
an optimal environment for hydrolases that catalyze the degradation of 
macromolecules and the production of amino acids, monosaccharides, and free 
fatty acids, which are exported throughout the cell via permeases (Jezegou et al., 
2012, Rong et al., 2012, Liu et al., 2012, Sagne et al., 2001). The multiple 
endocytic pathways, including phagocytosis, macropinocytosis, clathrin and 
caveolin-dependent and -independent endocytosis, import macromolecules from 
the extracellular space to the endolysosome system for degradation (Conner and 
Schmid, 2003, Di Fiore and von Zastrow, 2014, Goldstein and Brown, 2015). It is 
through the self-catabolic process of autophagy that cytoplasmic 
macromolecules, damaged or misfolded proteins, and even entire organelles are 
captured and delivered to endolysosomes (Kaur and Debnath, 2015, Mizushima 
and Komatsu, 2011). Hence, endolysosomal processing of a variety of cargo is 
essential for the removal of cellular components, the elimination of damaged 
organelles, the termination of signal transduction, and the maintenance of 
metabolic homeostasis. These functions underscore the fundamental role of 
endolysosomes in maintaining cellular health. 
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 Endolysosomes are storage sites for ions including H+, Na+, K+, Cl-, Ca2+, 
Zn2+, Fe3+, and Fe2+ (Xu and Ren, 2015, Xiong and Zhu, 2016b) as they integrate 
and digest materials compartmentalized by endocytosis, phagocytosis or 
autophagy. These endolysosome ions have key roles in cellular functions. As 
known, H+ ions are important in maintaining the acidic environment, which 
provides an optimal environment for the activity of endolysosomal digestive 
enzymes (Mindell, 2012a). Ca2+ plays a role in vesicle trafficking (Wong et al., 
2012), and Na+ is important in the function of endolysosome transporters, 
including the SLC38 family transporters (Mackenzie and Erickson, 2004, Wang et 
al., 2015). K+ is known to regulate the membrane potential of endolysosomes as 
well as the Ca2+ homeostasis of endolysosomes (Cang et al., 2015, Cao et al., 
2015). Cl− regulates the membrane potential of endolysosomes as a counter-ion 
and also facilitates acidification of endolysosomes (Kasper et al., 2005, Lange et 
al., 2006). Fe2+ catalyzes the hydrolysis of H2O2 and produces reactive oxygen 
species (Dixon et al., 2012, Fenton, 1894). And, Zn2+ serves as a key coenzyme 
for many proteins (Tapiero and Tew, 2003). In addition, there are ion channels 
and transporters that mediate the flux or transport of these ions across 
endolysosomal membranes. As an example, two pore channels (TPCs) conduct 
Na+ and Ca2+ release from endolysosomes (Ishibashi et al., 2000, Calcraft et al., 
2009, Wang et al., 2012), and transient receptor potential mucolipin (TRPML) 
channels form non-selective cation channels on endolysosome membranes that 
are permeable to many types of positively charged ions (Dong et al., 2008, 
Eichelsdoerfer et al., 2010). Furthermore, defects in ion exchange can lead to 
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abnormal endolysosome morphology, defective vesicle trafficking, impaired 
autophagy, and diseases such as neurodegeneration and lysosomal storage 
disorders (Wong et al., 2012, Kasper et al., 2005, Cang et al., 2015, Lange et al., 
2006). Therefore, ions within endolysosomes play critical roles in maintaining 
endolysosomal function and these same ions can regulate cell survival.  
 Drug-induced de-acidification of the endolysosomes causes an efflux of 
cations such as Ca2+ from endolysosomes into the cytosol (Christensen et al., 
2002, Fernández et al., 2016b). These released cations then play crucial roles in 
exploiting cellular signaling pathways including endolysosomal exocytosis 
(Cheng et al., 2014, Medina et al., 2011). Thus, it has been important to 
determine the concentrations of endolysosomal ions to fully understand the roles 
they play in cellular function and dysfunction, as well as drug-induced 
ramifications due to altered ion homeostasis within endolysosomes. In 
endolysosomes, Na+ concentrations are in the range of 20-140 mM and K+ 
concentrations are in the range of 2-50 mM; both play key roles in controlling 
endolysosome acidification (Steinberg et al., 2010, Wang et al., 2012). Ca2+ 
concentration in endolysosomes is about 0.5 mM (Christensen et al., 2002, 
Lloyd-Evans et al., 2008), and Ca2+ efflux from endolysosomes is known to be 
important for signal transduction, organelle homeostasis, and organelle 
acidification (Luzio et al., 2000, Dong et al., 2010, Luzio et al., 2007, Morgan et 
al., 2011). Cl- concentrations within endolysosomes are about 80 mM (Stauber 
and Jentsch, 2013) and affect the function of catabolite exporters and regulate 
Ca2+ release (DeFelice and Goswami, 2007, Saito et al., 2007). Although 
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endolysosomes are the intracellular source of ferric iron (Fe3+) and ferrous iron 
(Fe2+), little to nothing is known about the level of ferrous iron stored within 
endolysosomes. One review article stated that Fe2+ ions within endolysosomes 
are in the low micromolar range (2-5 µM) because a higher ferrous iron 
concentration would lead to elevated ROS causing cell damage (Kiselyov et al., 
2011, Mills et al., 2010). However, the referred to study used the cytosolic iron 
stain Phen-Green to measure intracellular labile iron, which is not a 
measurement of endolysosome iron concentrations. Upon a further literature 
search, the Fe2+ concentration within endolysosomes was not found, possibly 
due to a lack of available probes. With ferrous iron being important in the 
formation of reactive oxygen species and oxidative damage, it is important to 
determine endolysosome levels of ferrous iron.  
Fenton Reaction, Haber-Weiss Reactions, and Reactive Oxygen Species 
 In 1894, H.J.H Fenton discovered that several metals have a special 
oxygen transfer property which improves the use of hydrogen peroxide. Since 
this discovery the iron-catalyzed production of hydrogen peroxide has been 
called Fenton’s reaction (Fenton, 1894). In addition, Fritz Haber and his student 
Joshua Weiss in 1932 developed the Haber-Weiss reaction in which hydroxyl 
radicals are generated from hydrogen peroxide and superoxide (Weiss, 1934). 
The main finding by Haber and Weiss was that hydrogen peroxide is 
decomposed by a chain reaction (Koppenol, 2001) and it proceeds by successive 
steps as shown below in Figure 1.2. Ferrous iron within the cell, known as free 
labile iron or chelatable iron, is a key reactant in the formation of the highly 
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Figure 1. 2.  Fenton and Haber-Weiss Reactions: H.J.H Fenton discovered 
that iron catalyzed hydrogen peroxide, and Haber and Weiss 
discovered hydroxyl radicals are generated from hydrogen 
peroxide and superoxide. 
reactive hydroxyl radical (HO.) from H2O2 and superoxide (O2-) from O2, which 
damages DNA, proteins, and membranes (Fenton, 1894) (Kehrer, 2000). The 
generation of reactive oxygen species (ROS) contributes to cellular dysfunction 
and cell death from oxidative stress and ischemia or reperfusion (Jaeschke et al., 
2002, Videla et al., 2003, Schwabe and Brenner, 2006). In 1970, there was an 
emerging interest for the effect of free radicals on ageing mechanisms of living 
cells due to oxygen (O2), so it was proposed that the Haber–Weiss reaction was 
a source of radicals responsible for cellular oxidative stress. However, this 
hypothesis was later disproved (Koppenol, 2001). The oxidative stress toxicity is 
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not caused by the Haber–Weiss reaction as a whole, but by the Fenton reaction, 
which is one specific part of it (Koppenol, 2001). 
Mitochondria, ROS, and Cellular Dysfunction 
 The term “mitochondria” was coined by Carl Benda in 1898 (Benda, 1898, 
Ernster and Schatz, 1981). Friedrich Meves made the first recorded observation 
of mitochondria in plants in 1904, and in 1925 the respiratory chain was 
described when David Keilin discovered cytochromes (Ernster and Schatz, 
1981). A mitochondrion is a double-membrane bound organelle in eukaryotic 
cells that generates most of the cell’s adenosine triphosphate (ATP) as a 
chemical source of energy; thus, mitochondria are termed the “powerhouse” of 
the cell (Siekevitz, 1957). In addition, mitochondria have key roles in signaling, 
cellular differentiation, cell death, and controlling the cell cycle and cell growth 
(McBride et al., 2006). Therefore, it is not surprising that mitochondrial 
dysfunction has been implicated in human disease including cardiac dysfunction 
(Lesnefsky et al., 2001), heart failure (Dorn et al., 2015), autism (Griffiths and 
Levy, 2017), and neurodegenerative diseases (Johri and Beal, 2012).  
 Mitochondria are an important source of ROS and they participate in redox 
signaling throughout cells (Andreyev et al., 2005, Muller, 2000, Balaban et al., 
2005). The first report that the respiratory chain produced ROS came in 1966 
(Jensen, 1966), which was followed by the pioneering work of Chance and his 
colleagues in 1979 who showed that isolated mitochondria produce H2O2 
(Chance et al., 1979). Later, it was confirmed that H2O2 generated within 
mitochondria was catalyzed from the dismutation of superoxide (Loschen et al., 
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1974). Near the same time, it was discovered that mitochondria contain their own 
SOD (superoxide dismutase) and MnSOD (manganese superoxide dismutase), 
which confirmed the biological significance of mitochondrial superoxide 
production (Weisiger and Fridovich, 1973). Since then, the literature has further 
elucidated the sources and consequences of mitochondrial ROS production and 
how it contributes to cellular dysfunction and a range of pathologies (Balaban et 
al., 2005, Droge, 2002). Specifically, it is now known that ROS production leads 
to oxidative damage of proteins, membranes, lipids, and DNA, as well as 
impairing mitochondria from synthesizing ATP and conducting normal metabolic 
functions such as amino acid metabolism, the tricarboxylic acid cycle, the urea 
cycle, and Fe-S assembly as shown in Figure 1.3 (Murphy, 2009).  
 Mitochondria have important functions in iron metabolism that includes the 
synthesis of iron-sulfur clusters (ISCs) and heme; both are vital for normal cell 
function. Iron is an important molecule involved in the electron transport chain 
because 12 proteins contain ISCs and 8 proteins contain heme in their active 
centers (Rouault and Tong, 2005). Further, mitochondria have a readily-available 
pool of redox-active iron (Petrat et al., 2002), and an increase in this iron pool 
directly associates with an increase in oxidative damage (Pelizzoni et al., 2011, 
Kumfu et al., 2012). Thus, mitochondrial iron levels are tightly regulated because 
a shortage affects processes that require iron as a co-factor such as the electron 
transport chain, whereas an excess of redox-active iron promotes the generation 
of elevated levels of ROS. Not surprisingly, mitochondrial iron accumulation has 
been associated with diseases including cancer and neurodegenerative diseases 
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Figure 1. 3.  Effects of mitochondrial ROS on cell physiology. ROS production 
within mitochondria leads to oxidative damage to proteins, 
membranes, lipids, and DNA, as well as impair mitochondria to 
synthesize ATP and carry out normal metabolic functions. 
Oxidative damage within mitochondria causes the release of 
cytochrome c to the cytosol and activating apoptosis, thus, 
mitochondrial damage contributes to a wide range of diseases. 
(Cited from Murphy, M., Biochemical Journal, 2009) 
(Zecca et al., 2004, Andersen et al., 2014, Urrutia et al., 2014, Enns, 2003). 
Cancer cells have a much higher requirement for iron and are sensitive to iron 
depletion (Richardson et al., 2009), and studies have shown that iron chelators 
induce apoptosis in cancer cells in vitro and reduce tumor size in vivo 
(Richardson et al., 2009, Kalinowski and Richardson, 2007). However, the 
mechanism of action by which iron chelators affect physiological and pathological 
processes are not fully understood (Bystrom et al., 2014). Although iron 
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metabolism and mitochondrial iron has been studied extensively, it still remains 
unclear where the excess iron in mitochondria is coming from and whether or not 
mitochondrial iron accumulation is a downstream or upstream event of disease. 
Deferoxamine (DFO) 
 Deferoxamine (DFO), otherwise known as Desferal or desferoxamine, is 
an iron chelator that was approved for medical use in 1968 (Ballas et al., 2018). 
Clinically, it is the only iron chelator proven of benefit and is used as adjunctive 
therapy for patients with acute iron overload or hemochromatosis (Mobarra et al., 
2016). DFO binds ferric and ferrous iron tightly rendering the molecule inactive 
and incapable of catalyzing redox reactions. DFO is used to treat iron overload 
because it has a large preference for iron over other ions such as calcium 
(Kd=10-31 M for iron, Kd=10-9 M for calcium) (Keberle, 1964). Iron ions have six 
electrochemical coordination sites, and a chelator molecule that binds all six sites 
completely inactivates labile iron. These chelators are termed hexidentate, and 
DFO is an example that chelates iron in a one-to-one ratio (Keberle, 1964). 
Furthermore, it has been shown that DFO cannot enter the cell by passive 
diffusion but enters the cell by endocytosis and remains within endolysosomes 
(Doulias et al., 2003, Lloyd et al., 1991b).  
Rationale, Purpose, and Hypotheses 
 Previous studies have emphasized the importance of measuring the 
concentration of ferrous iron in endolysosomes, which could lead to determining 
the extent to which and the mechanisms by which endolysosome Fe2+ plays a 
role in cellular processes (Xiong and Zhu, 2016b). However, to-date there are no 
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available probes with which to assess endolysosome Fe2+. Therefore, the 
purpose of the first study, outlined in Chapter 2, is to characterize a fluorescence 
probe that might be specific for ferrous iron within endolysosomes and that might 
find use as a probe to measure the iron concentrations in various types of cells. 
The hypothesis to be tested in our first study was that FeRhonox-1 is highly 
specific for Fe2+ molecules, localizes to endolysosomes, and it can be used to 
determine the role of endolysosome Fe2+ in cellular mechanisms. 
 Previous studies have shown that de-acidification of endolysosomes 
induced by certain drugs such as bafilomycin A1 and chloroquine causes a 
release of Ca2+ from endolysosomes into the cytosol (Christensen et al., 2002, 
Fernández et al., 2016b). In addition, previous works have determined the 
significant role iron plays in mitochondrial damage without the knowledge of 
where excess iron is coming from (Stehling et al., 2013, Carroll et al., 2011). 
Therefore, the purpose of the second study, outlined in Chapter 3, is to 
determine the role of endolysosome ferrous iron in inter-organelle communication 
with mitochondria. The hypothesis of this study is that ferrous iron within 
endolysosomes is translocated to the mitochondria induced by the 
pharmacological agents’ chloroquine and bafilomycin A1 that de-acidify the 
endolysosomes. The increase in mitochondrial iron leads to increased ROS 
levels and cell death.  
 The third study, outlined in Chapter 4, is an extension of the second study 
but looking at drugs of abuse. Drugs of abuse have been associated with 
neurodegenerative disorders, and, more specifically, evidence shows that drugs 
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of abuse increase free radicals and mitochondrial dysfunction such as decreased 
cellular energy production (Xu et al., 2011, Cunha-Oliveira et al., 2013). The 
purpose of this study is to determine if a drug of abuse, morphine, causes 
mitochondrial dysfunction due to endolysosome communication by Fe2+. The 
hypothesis of this study is that morphine de-acidifies endolysosome pH releasing 
Fe2+ into the cytosol and then taken up by the mitochondria leading to 
mitochondrial ROS.  
 The fourth study, outlined in Chapter 5, which is also an extension of the 
second study looks at HIV-1 associated proteins and their effect on 
endolysosomes and mitochondrial communication by exploiting iron. Previous 
studies have shown that the HIV-1 associated proteins glycoprotein (gp120) and 
trans-activator of transcription protein (Tat) exploit endolysosome Ca2+ and pH 
(Nath et al., 1995, Hui et al., 2012b)). Thus, the purpose of this study is to 
determine the role of gp120 in endolysosome and mitochondria communication 
by iron. The hypothesis of this study is that gp120 de-acidifies endolysosome, 
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Abstract 
 Endosomes and lysosomes (endolysosomes) are acidic organelles that 
are important both physiologically and pathologically. Implicated in the 
physiological and pathophysiological processes regulated by endolysosomes are 
readily releasable stores of cations including ferrous iron (Fe2+); an essential 
cofactor for the generation of reactive oxygen species (ROS). In determining the 
extent to which and mechanisms by which Fe2+ released from endolysosomes 
affects cellular functions it was important to determine levels of Fe2+ in 
endolysosomes. In some cells and by other researchers, FeRhoNox-1 was found 
to detect Fe2+ in acidic organelles known as Golgi. Here, using U87MG 
astrocytoma cells and primary cultures of rat neurons we report that FeRhoNox-1 
is highly specific for Fe2+, that FeRhoNox-1 positive stores are largely localized in 
endolysosomes and not in Golgi, that control levels of Fe2+ were 36.3 ± 13.6 µM 
in endolysosomes, and that the stores of Fe2+ in endolysosomes increased to 
75 ± 15.7 µM when cells were incubated with ferric ammonium citrate and 
decreased to 0.08 ± 0.05 µM when cells were incubated with the iron chelator 
deferoxamine. Furthermore, subpopulations of endolysosomes exist with 
extensive variability in Fe2+ content. Our findings demonstrate the utility of using 
FeRhoNox-1 to measure Fe2+ stores in endolysosomes and suggest that this 
probe will find important uses in better understanding cellular events downstream 
of released endolysosome Fe2+. 
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Introduction 
 The existence and functional significance of lysosomes and endosomes 
was honored with Nobel prizes for lysosomes in 1955 (de Duve, 2005) and for 
endosomes and endocytosis in 1985 (Motulsky, 1986). Endosomes and 
lysosomes (here after referred to as endolysosomes) are now known to regulate 
many physiological functions including plasma membrane repair, cell 
homeostasis, energy metabolism, nutrient-dependent signal transduction, and 
immune responses (Perera and Zoncu, 2016, Settembre and Ballabio, 2013). 
Pathologically, morphological and functional changes to endolysosomes have 
been described for a wide spectrum of diseases including cancer and 
neurodegenerative diseases (Colacurcio and Nixon, 2016). 
 A defining feature of endolysosomes is their acidic luminal pH; a discovery 
that predates the description of lysosomes by 60 years (Lellouch, 1993). 
Endolysosome acidification is mainly regulated by vacuolar-ATPase that drives 
protons against their electrochemical gradients into the lumen of endolysosomes 
(Perera and Zoncu, 2016). Such transmembrane proton gradients are well known 
to exist in endolysosomes as well as in mitochondria, Golgi complex, secretory 
granules, and plasma membranes (Mindell, 2012a). Endolysosome acidity is also 
essential for the functionality of 60 different hydrolase enzymes and the fusing of 
autophagosomes with lysosomes to form autophagolysosomes (Ktistakis and 
Tooze, 2016). 
 Endolysosomes are known to contain high levels of transition metals 
including iron, copper and zinc as well as readily releasable stores of calcium 
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(Hui et al., 2015, Xu and Ren, 2015). Iron, in particular, is essential for a variety 
of important biological events and iron overload has been implicated in such 
diseases as cancer and neurodegenerative diseases. Ferric iron (Fe3+) bound to 
transferrin enters cells by endocytosis whereupon it is reduced to unbound labile 
ferrous iron (Fe2+). Because of the importance of Fe2+ as a catalyst of Fenton and 
Haber-Weiss reactions that generate potentially toxic levels of reactive oxygen 
species (ROS), it is important to know the extent to which and the mechanisms 
by which Fe2+ exits endolysosomes and enters the cytosol and mitochondria.  
 About five years ago, the fluorescence ‘turn-on’ probe FeRhoNox-1 was 
found to have pronounced specificity for Fe2+ versus other biologically relevant 
metal ions (Mukaide et al., 2014). It was also shown that FeRhoNox-1 labels Fe2+ 
stores in acidic Golgi organelles at least in some cells (Hirayama et al., 2013). 
However, to date, no reports have appeared determining whether FeRhoNox-1 
labels Fe2+ alternatively in endolysosomes and whether FeRhoNox-1 can be 
used to quantitatively measure levels of Fe2+ in endolysosomes. Here, we report 
that FeRhoNox-1 was highly specific for Fe2+ versus other cations such as 
calcium, magnesium, copper and zinc. Further, FeRhoNox-1 positive stores were 
selectively localized in endolysosomes and that subpopulations of 
endolysosomes exist with extensive variability in Fe2+ content. And, finally as a 
proof of principle for quantitative measurements of labile iron stores, 
endolysosome Fe2+ stores were increased with ferric ammonium citrate 
supplementation and were decreased with the iron chelator deferoxamine. It is 
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likely that FeRhoNox-1 will find extensive use for better understanding the 
physiological relevance and pathological significance of Fe2+ in living cells.  
Materials and Methods 
Cultures of U87MG Astrocytoma Cells  
 U87MG cells were cultured in DMEM (Invitrogen) supplemented with 
10% fetal calf serum and penicillin/streptomycin (Invitrogen). Cells were grown to 
about 40% confluence (~15,000 cells) in 35 mm2 plastic culture dishes coated 
with poly-D-lysine in a 37oC and 5% CO2 environment.  
Primary Cultures of Rat Neurons  
 Primary neuronal cultures were prepared with cortical tissue from male 
and female Holtzman E17 rat embryos, as we have previously described (Festa 
et al., 2015, Sengupta et al., 2009, Pitcher et al., 2014). We prepare two different 
types of primary neuronal cultures, which allow for isolation of cortical neurons in 
the presence or absence of glia. Most of the experiments used primary cortical 
neurons grown in the absence of glia (neurobasal cultures), as originally 
described by (Brewer et al., 1993). Briefly, dissected cortical neurons were plated 
in Neurobasal medium containing 2% heat inactivated horse serum (Hyclone), 
2% B-27 supplement 50X (Gibco), 1% GlutaMAX (Gibco), and X uM L-Glutamic 
acid (Tocris 0218) for the first four hours of culture. Next, cultures were washed 
with neurobasal medium, before replacement with the same neurobasal medium 
formula, without horse serum. On fifth day in vitro (DIV 5), medium was replaced 
with neurobasal, containing 2% B27 and 1% Glutamax; the medium was 
changed every four days for the rest of the culture.  Select experiments used 
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primary cortical neurons cultured in the presence of a glial feeder layer (bilaminar 
cultures), as we described previously (Shimizu et al., 2011). The bilaminar 
culture system is more similar to the in vivo environment due to the presence of 
glia during neuronal maturation and throughout the culture; however, it still 
enables direct investigation of neurons, as they can be separated from the glial 
layer. Dissected primary neurons were plated in DMEM with 10% heat 
inactivated horse serum (Hyclone) for four hours. Following a wash with DMEM, 
culture media was changed to DMEM containing 1% N2.1 supplement (Gibco), 
and X mg Ovalbumin (Sigma). One-half of the culture medium was replaced 
every 7 DIV. Neurons were typically used for experiments from day 9-14 in vitro.  
FeRhoNox-1 Specificity for Fe2+ 
 To determine the specificity of FeRhoNox-1 for Fe2+, we first used a cell-
free system and a LSM800 laser scanning microscope system (Zeiss). 
FeRhoNox-1 was added to plates at a final concentration of 10 µM, and FeCl2, 
FeCl3, MgCl2, CaCl2, and ZnCl2 were added at final concentrations ranging from 
1 to 1000 µM in water. Following the addition of the reagents, plates were 
incubated at room temperature for 1 h and then analyzed at an excitation 
wavelength of 537 nm and an emission wavelength of 569 nm.  
Identification of FeRhoNox-1 Positive Organelles in U87MG Cells 
 Individual culture dishes containing U87MG cells were incubated with 
FeRhoNox-1 (10 µM) for 1 h, washed 3-times with PBS, and then imaged using a 
LSM800 laser scanning microscope system (Zeiss) at excitation and emission 
wavelengths of 537 and 569 nm, respectively. U87MG cells were incubated with 
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the late endosome/lysosome marker LysoTracker Green DND-26 (10 µM, 
Invitrogen) for 30 min at 37°C. Fields were chosen at random and at least five 
images from every experimental condition were acquired by confocal microscopy 
(LSM800, Zeiss). Pearson correlation coefficients were then determined for the 
colocalization of FeRhoNox-1 positive and LysoTracker-positive endolysosomes 
after the images were merged. Using Imaris software the LisICQ was determined 
for colocalization of FeRhonox-1 positive and LysoTracker-positive 
endolysosomes. 
Identification of Golgi-Positive Organelles in U87MG Cells  
 CellLight™ Golgi-GFP, BacMam 2.0 (ThermoFisher) was used to stain 
Golgi. Golgi-GFP was added to dishes of U87MG cells at a concentration of  
1 × 108 CellLight® particles/mL and after incubating cells overnight at 37oC in a 
5% CO2 environment, cells were washed 3-times with PBS and then imaged 
using confocal microscopy (LSM800, Zeiss) at excitation and emission 
wavelengths 488 and 510 nm, respectively. Pearson correlation coefficients were 
then determined for the colocalization of FeRhoNox-1 positive and LysoTracker-
positive endolysosomes after the images were merged.  
Materials 
 FeRhoNox-1 was purchased from Goryo Chemical Company (Japan). All 
other reagents including FeCl2, FeCl3, MgCl2, CaCl2, and ZnCl2 were obtained 




 All data were presented as means + standard deviation (SD). Statistical 
significance between two groups was analyzed with a Student’s t-test, and 
statistical significance among multiple groups was analyzed with one-way 
ANOVA plus a Tukey post-hoc test. p<0.05 was accepted to be statistically 
significant. Pearson Correlation Coefficients were performed using ImageJ 
software.  
Results 
FeRhoNox-1 specificity for Fe2+ 
 We first determined the specificity with which FeRhoNox-1 labels Fe2+. 
FeRhoNox-1 at a concentration of (5 μM) was incubated for 1 h in the absence or 
presence of FeCl2, FeCl3, MgCl2, CaCl2, and ZnCl2 at final concentrations 
ranging from 1 to 1000 µM. Following the incubations, aliquots were imaged by 
confocal microscopy. FeRhoNox-1 fluorescence was found to be highly specific 
for Fe2+ and not Fe3+ (Figure 2.1). FeRhoNox-1 fluorescence did not increase 
significantly in the presence of MgCl2, CaCl2 or ZnCl2 at any of the 
concentrations tested (see Supplemental Figure S.2.A.).  
FeRhoNox-1 labels endolysosome stores of Fe2+ 
 We next determined the extent to which FeRhoNox-1 positive stores of 
Fe2+ colocalized with LysoTracker-positive endolysosomes. Confocal microscope 
images of FeRhoNox-1 positive staining showed a normally distributed pattern of 
endolysosome staining (Figure 2.2). The late endosome/lysosome marker 
LysoTracker showed a staining pattern similar to that observed for FeRhoNox-1 
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in U87MG cells (Figure 2) and in primary cultures of rat neurons (Data not 
shown). When the images for FeRhoNox-1 and LysoTracker were merged, the 
staining patterns showed a very high degree of colocalization; the Pearson 
correlation coefficient for the colocalization was 0.84 + 0.03.  
 To further differentiate the observed localization of FeRhoNox-1 in 
endolysosomes, we determined next the extent to which FeRhoNox-1 staining 
colocalized with EEA1-positive early endosomes and LAMP1-positive late 
endosomes/lysosomes. As expected, confocal microscope images of FeRhoNox-
1 positive staining showed a normally distributed pattern of staining (Figure 2.3). 
The FeRhoNox-1-positive staining showed a very high degree of colocalization 
with EEA1-positive endosomes; the Pearson correlation coefficient for RhoNox-1 
and EEA1 colocalization was 0.86 + 0.04. The FeRhoNox-1-positive staining also 
showed a moderate degree of colocalization with the LAMP1-positive late 
endosomes/lysosomes; the Pearson correlation coefficient for FeRhoNox-1 and 
LAMP1 colocalization was 0.56 + 0.05. 
FeRhoNox-1 Positive Stores of Fe2+ Were Not Highly Expressed in Golgi 
 Having observed FeRhoNox-1 positive staining in endosomes and 
lysosomes, we next wanted to specifically determine the extent to which 
FeRhoNox-1 positive staining might also be co-localized in Golgi. FeRhoNox-1-
positive and Golgi Tracker-positive Golgi staining was observed in U87MG cells, 
but the staining patterns showed distinct differences (Figure 2.4). When the 
images were merged, FeRhoNox-1-positive staining a weak degree of 
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colocalization with Golgi Tracker-positive staining (Figure 2.4); the Pearson 
correlation coefficient for the colocalization was 0.13 + 0.06. 
FeRhoNox-1 Fluorescence Intensity Increased with Ferric Ammonium 
Citrate (FAC) and Decreased with Deferoxamine (DFO) 
 As a proof of principle for the utility of FeRhoNox-1 to measure 
quantitatively labile levels of iron, we next determined the extent to which 
increasing or decreasing levels of Fe2+ in endolysosomes were reflected by 
changes in FeRhoNox-1 fluorescence intensity. Incubation of U87MG cells for 
1 h with FAC (50 µM) to increase levels of endolysosome Fe2+ resulted in 
statistically significant (p<0.001) increases in FeRhoNox-1 fluorescence intensity 
to 146 ± 6 % from that of normal control cells of 101 ± 5 % (Figure 5B,D). 
Incubation of U87MG cells for 1 h with the iron chelator DFO (25 µM) to decrease 
levels of Fe2+ in endolysosomes resulted in statistically significant (p<0.0001) 
decreases in FeRhoNox-1 fluorescence intensity to 51 ± 5 % of control values 
(Figure 5C,D). Because little is known about quantitative levels of Fe2+ in 
endolysosomes we next developed a standard curve of the FeRhoNox-
1/Lysotracker ratios at concentrations of Fe2+ ranging from 10 to 100 µM. We 
observed a very strong linear relationship between FeRhoNox-1/Lysotracker 
ratios and Fe2+; the Pearson correlation coefficient for the colocalization was  
0.92 + 0.02 (Figure 5E). Using this standard curve, we determined that levels of 
Fe2+ under normal conditions were 36.3 + 13.6 µM, and that levels of Fe2+ were 
75.0 + 15.7 µM in cells pretreated with FAC and were 0.08 + 0.05 µM in cells 
pretreated with DFO (Figure 5E).  
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Intracellular Endolysosome Fe2+ Concentration Variability  
 Qualitatively, it appeared that concentrations of Fe2+ varied greatly among 
endolysosomes in individual cells. In order to measure quantitatively, the range 
of Fe2+ contained in subpopulations of endolysosomes we first developed a 
standard concentration-response relationship of the FeRhonox-1/LysoTracker 
ratio using a cell-free system. Individual endolysosome Fe2+ levels were 
measured and the data were separated into bins of 0-25, 26-50, 51-75, 76-100, 
and 100-150 µM (Figure 6). Although the average concentration of Fe2+ under 
normal conditions was 36.3 + 13.6 µM, the concentrations of Fe2+ in 
endolysosomes varied greatly and ranged from undetectable to over 100 µM.  
Discussion 
 Intracellular labile iron regulates a variety of physiological functions and 
increased levels of intracellular Fe2+ have been implicated in the genesis of a 
number of pathological conditions including cancer and neurodegenerative 
diseases (Rockfield et al., 2017, Padmanabhan et al., 2015). In non-intestinal 
cells, virtually all Fe3+ is endocytosed bound to transferrin whereupon it is 
reduced in endolysosomes to Fe2+ (Kurz et al., 2011). Thus, it is very important to 
be able to measure levels of Fe2+ in endolysosomes to appreciate its 
physiological roles and pathological relevance. However, due in part to the lack 
of probes with which to study endolysosome stores of Fe2+, it has been difficult to 
determine the degree to which and the mechanisms by which endolysosome 
Fe2+ affects physiologically- and pathologically-relevant processes. One such 
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probe is FeRhoNox-1; a highly selective turn-on fluorescence compound capable 
of detecting levels of Fe2+ in acidic organelles (Hirayama et al., 2013).  
 In agreement with previous studies (Hirayama et al., 2013, Mukaide et al., 
2014) we found that FeRhoNox-1 was highly selective for Fe2+; no significant 
increases in fluorescence were observed with Fe3+, zinc, copper, magnesium or 
calcium. When studies were conducted by others with human hepatocellular 
carcinoma cells (HepG2) and human breast cancer cells (MCF-7), a staining 
pattern consistent with FeRhoNox-1 positive staining of Golgi was reported 
(Hirayama et al., 2013). However, no co-distribution studies were conducted with 
markers for endolysosomes. Here, we report that FeRhoNox-1 stained 
endolysosome-positive stores of Fe2+ with very high correlation coefficients for 
the co-localization with markers for endolysosomes (LysoTracker), early 
endosomes (EEA1), and late endosomes/lysosomes (LAMP1). For example, the 
high correlation between LysoTracker and FeRhoNox-1 staining of 0.84 + 0.03 
that we found in U87MG astrocytoma cells and in primary cultures of rat neurons 
is virtually identical to that just reported for a different endolysosome-specific Fe2+ 
probe (Hirayama, 2018). On the other hand, we found a low correlation between 
FeRhoNox-1 staining and Golgi staining. Even qualitatively, the FeRhoNox-1 
staining we observed was consistent with the punctate nature of endolysosomes 
and was very different from the wispy nature of Golgi.  
 Although it has been reported that FeRhoNox-1 can exhibit marked 
background fluorescence signals (Niwa et al., 2014), in our studies the 
background fluorescence was limited and easily corrected for. With this 
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technique, we were able to detect increased levels of endolysosome Fe2+ 
following incubation of U87 cells with FAC and decreased levels following 
incubation with the Fe2+ chelating compound DFO that is known to specifically 
enter cells by endocytosis and once endocytosed DFO resides in endolysosomes 
for extended periods of time (Lloyd et al., 1991). We also noted that 
subpopulations of endolysosomes exist and can be differentiated on the basis of 
their Fe2+ content. While it is unclear why the Fe2+ content is so variable, one 
possibility is related to the differences noted in endolysosome pH depending on 
their positions in cells and findings that endolysosome de-acidification causes 
Fe2+ to be released from endolysosomes (Uchiyama et al., 2008). However, 
FeRhoNox-1 staining was not sensitive to changes in pH (see Supplemental 
Figure S.2.B.) and so the differences in staining were likely due to the content of 
Fe2+ and not the pH of the endolysosome. Thus, FeRhoNox-1 is a useful probe 
with which to detect relative and absolute levels of endolysosome Fe2+ and with 
this probe others and we can investigate further the physiological and 
pathological roles of this releasable and biologically-active store of Fe2+.  
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Figure 2. 1.  FeRhoNox-1 fluorescence intensity increased with increased 
concentrations of FeCl2. FeCl2 (closed circles) and FeCl3 (closed 
squares) were incubated at concentrations ranging from 1 to 
100 μM and FeRhoNox-1 (10 μM) in a cell-free environment. 
Solutions were incubated for 1 h and aliquots were imaged by 
confocal microscopy (LSM800, Zeiss) with a 63X oil objective 





Figure 2. 2.  FeRhoNox-1 labeled endolysosome stores of Fe2+. FeRhoNox-1-
positive stores (red) of Fe2+ (FeRhoNox-1) and LysoTracker-
positive (green) endolysosomes (LysoTracker) were observed in 
U87MG cells. The FeRhoNox-1 positive staining showed a very 
high degree of colocalization with the LysoTracker-positive 
endolysosomes when the images were merged (Merged). The 
Pearson correlation coefficient for the colocalization determined 
from three independent experiments was 0.84 + 0.03. Scale bar 




Figure 2. 3. FeRhoNox-1 labeled Fe2+ stores in endosomes and lysosomes. FeRhoNox-1-positive stores 
of Fe2+ (FeRhoNox-1, red), EEA1-positive early endosomes (EEA1, green), and LAMP1-
positive late endosomes/lysosomes (LAMP1, yellow) were observed in U87MG cells. The 
FeRhoNox-1 positive staining showed a very high degree of colocalization with the EEA1-
positive endosomes and a high degree of colocalization with the LAMP1-positive lysosomes 
when the images were merged (Merged). The Pearson correlation coefficients determined 
from three independent experiments for FeRhoNox-1 and EEA1 colocalization was 0.86 + 





Figure 2. 4.  FeRhoNox-1 positive staining was not strongly correlated with Golgi staining. FeRhoNox-1 positive 
stores of Fe2+ (FeRhoNox-1, red) and Golgi Tracker-positive Golgi (Golgi Tracker, green) were 
observed in U87MG cells. The FeRhoNox-1 positive staining showed a low degree of colocalization 
with the Golgi Tracker-positive staining when the images were merged (Merged). The upper three 
images were observed at a lower magnification (scale bar is 5 µm) than were the lower three images 
(scale bar is 2 µm). The Pearson correlation coefficient for the colocalization determined from three 




Figure 2. 5.  FeRhoNox-1 fluorescence intensity increased with FAC and 
decreased with deferoxamine.  
(A.) As expected, we observed a high level of colocalization 
between FeRhoNox-1 and LysoTracker staining of 
endolysosomes (Control). 
(B.) Preincubation of U87MG cells with 50 µM ferric ammonium 
citrate (FAC) for 1 h increased FeRhoNox-1 fluorescence 
staining in endolysosomes.  
(C.) Preincubation of U87MG cells with 25 µM deferoxamine 
(DFO) for 1 h reduced FeRhoNox-1 fluorescence staining in 
endolysosomes.  
(D.) The quantification of FeRhoNox-1 fluorescence intensity for 
control cells, and cells treated with FAC and DFO.  
(E.) A standard dose-response relationship for FeRhoNox-1 and 
Lysotracker staining was developed in a cell-free system. The 
dose-response relationship was then used to quantify Fe2+ levels 
in endolysosomes of normal cells (square box) as well as in cells 







Figure 2. 6.  Intracellular endolysosome Fe2+ concentration variability: 
Qualitatively, it appeared that concentrations of Fe2+ varied 
greatly among endolysosomes in individual cells. In order to 
measure quantitatively, the range of Fe2+ contained in 
subpopulations of endolysosomes, we first developed a standard 
concentration-response relationship of the FeRhonox-
1/LysoTracker ratio using a cell-free system. Individual 
endolysosome Fe2+ levels were measured and the data were 
separated into bins of 0-25, 26-50, 51-75, 76-100, and  
100-150 µM. Although the average concentration of Fe2+ under 
normal conditions was 36.3 + 13.6 µM, the concentrations of 
Fe2+ in endolysosomes varied greatly and ranged from 
undetectable to over 100 µM. 
34 
 
Figure 2. A.  Supplemental Figure: RhoNox-1 does not increase with 
increased concentrations of ZnCl2, CaCl2, or MgCl2. ZnCl2, 
CaCl2, and MgCl2 were used at different concentrations along 
with FeRhoNox-1 (10 μM) in a cell free environment. The 
concentrations were incubated in a 1 ml tube for 1 hour and then 
added to an empty plate and imaged with a 63X oil objective and 




Figure 2. B.  Supplemental Figure: FeRhoNox-1 does not significantly change 
with pH: In a cell free system with changing pH values from 3 to 
6, the FeRhonox-1 fluorescent intensity does not significantly 
change. This illustrates that FeRhoNox-1 intensity is 
independent of pH changes. 
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 Mitochondria are subject to iron overload under a variety of conditions and 
disease states, but it is not clear what are the subcellular origins of this iron nor 
its consequences. Endosomes and lysosomes, referred to as endolysosomes, 
are storage sites of ferrous iron (Fe2+), and the degree to which and the precise 
mechanisms by which endolysosome Fe2+ contribute to iron-dependent changes 
to mitochondria and cell injury remains uncertain. Here, our studies were aimed 
to determine the role of inter-organellar signaling of Fe2+ from iron-rich 
endolysosomes to mitochondria under pharmacologically-induced conditions. We 
demonstrated, in U87MG astrocytoma cells, mouse primary hepatocytes, and 
primary cultures of rat cortical neurons, that Fe2+ within endolysosomes was 
translocated to the mitochondria resulting in mitochondrial dysfunction and cell 
death. The weak-base chloroquine and the vacuolar-ATPase inhibitor bafilomycin 
A1 both de-acidify endolysosomes and both induced the release of Fe2+ and this 
resulted in increased concentrations of Fe2+ in the cytoplasm and in 
mitochondria. Furthermore, the endocytosed iron chelator, deferoxamine, 
inhibited the release of bafilomycin A1- and chloroquine-induced release of 
endolysosome stores of Fe2+ and prevented the induced increases of ROS in 
cytoplasm and mitochondria. These findings demonstrate that redox-active Fe2+ 
in endolysosomes plays a key upstream role in mitochondrial iron accumulation 
and dysfunction, and deferoxamine might be potential adjunctive therapeutic 




 Although iron is an essential nutrient for cellular processes such as the 
electron transport chain, in excess it is a toxicant that can lead to acute cellular 
necrosis and injury (Christ et al., 1995). Excess iron may promote diseases such 
as diabetes, cancer, cardiovascular disease, and neurodegeneration (Swanson, 
2003, Petersen, 2005, Brewer, 2007, Imeryuz et al., 2007), and disrupted iron 
homeostasis appears to play an important role in disease pathogenesis (Enns, 
2003, Jellinger, 2009). These findings are further strengthened by observations 
that the iron chelator, deferoxamine (DFO), protects against the deleterious 
effects of iron in various models of oxidative stress and hypoxic/ischemic injury 
suggests a role for iron in the pathogenesis of variety of disorders and diseases 
(Starke and Farber, 1985). However, the intracellular source of excess iron and 
the precise mechanisms by which iron is mobilized to contribute to cellular injury 
remain poorly understood.  
 Ferrous iron (Fe2+), known as labile or chelatable iron, is a key reactant in 
the formation of the highly reactive hydroxyl radicals (HO.) from H2O2 and 
superoxide (O2-) radical from O2, both of which damage DNA, proteins, and 
membranes (Fenton, 1894) (Kehrer, 2000). The generation of reactive oxygen 
species (ROS), including O2- and HO, contribute to cellular dysfunction and cell 
death from oxidative stress, ischemia and ischemia-reperfusion (Jaeschke et al., 
2002, Videla et al., 2003, Schwabe and Brenner, 2006). The most important 
source of ROS is mitochondria through mechanisms linked to ATP production 
(Loschen et al., 1971, Loschen et al., 1974, Boveris and Cadenas, 1975). 
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Mitochondria have a constitutive presence of ROS from the electron transport 
chain, thus iron levels must be tightly regulated. However, the intracellular source 
of excess iron that leads to mitochondrial iron accumulation remains poorly 
understood. Furthermore, it is unclear whether mitochondrial iron accumulation 
causes or is a consequence of upstream events including ROS production and 
cell death (Mena et al., 2015).  
 Endosomes and lysosomes, referred to as endolysosomes, have many 
physiological roles including plasma membrane repair, cell homeostasis, cell 
adhesion and migration, apoptotic cell death, and metabolic signaling (Perera 
and Zoncu, 2016, Settembre et al., 2013). And it is well-known that 
endolysosomes are storage sites for readily-releasable cations including Ca2+, 
Zn2+, Fe3+, and Fe2+ (Xu and Ren, 2015, Xiong and Zhu, 2016). Furthermore, 
endolysosome-associated conductive cation channels like vacuolar-ATPase, 
transient receptor mucolipin type 1 channels (TRPML1), and two-pore channels 
(TPCs) regulate the homeostasis of cations and cation-based inter-organellar 
communication. The acidic pH of endolysosomes is maintained through the influx 
of protons via vacuolar-ATPases in conjunction with ion channels (TRPML1, 
TPCs and BK channels) and pH is known to affect cation concentrations in 
endolysosomes (Pu et al., 2016). The proton force generated by the vacuolar-
ATPase drives the movement of ions and small molecules across membranes, 
creating a voltage gradient which is sustained through counter-ions including 
Na+, K+, and Cl- (Mindell, 2012). Studies have shown endolysosome de-
acidification by bafilomycin A1 and chloroquine cause an efflux of cations such 
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as Ca2+ into the cytosol (Christensen et al., 2002, Fernández et al., 2016), and 
these released Ca2+ cations play crucial roles in exploiting cellular signaling 
pathways. However, little is known about the role of readily-releasable redox-
active Fe2+ in endolysosomes in inter-organellar signaling and cell death.  
 In this study, we showed that bafilomycin A1- and chloroquine-de-
acidification of endolysosomes causes an efflux of Fe2+ from endolysosomes and 
that this Fe2+ can accumulate in the cytoplasm and in mitochondria where it can 
contribute to ROS production and cell death. In addition, we demonstrated that 
DFO chelated endolysosome Fe2+ and blocked cytosolic and mitochondrial ROS 
induced by bafilomycin A1 and chloroquine as well as chloroquine- and 
bafilomycin A1-induced cell death. Furthermore, we demonstrated the 
involvement of two-pore channels in the release of Fe2+ cations from 
endolysosomes upon de-acidification and that mitochondrial permeability 
transition pores (MPTPs) uptake Fe2+ into mitochondria. 
Materials and Methods 
Cell Cultures 
 U87MG glioblastoma cells were cultured in 1x DMEM (Invitrogen) 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin 
(Invitrogen). Cells were grown to confluence in T75 flasks or 35 mm2 dishes to 
about 40% confluence in an environment of 5% CO2 at 37oC. Cells were only 
used at passage numbers of 10 or less. 
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Endolysosome pH 
 As previously described (Chen et al., 2013, Hui et al., 2012a, Hui et al., 
2012b), endolysosome pH was measured using a ratiometric indicator-dye, 
LysoSensor Yellow/Blue DND-160; a dual excitation dye that allows for the 
measurement of acidic organelles independent of dye loading efficiency. U87MG 
cells were loaded with 10 µM DND-160 for 5 minutes at 37°C. Post-incubation, 
dye-containing media was removed and PBS was added to the cells prior to 
them being taken for imaging. CellLight Lysosome-RFP (Thermosfisher), 
incubated in cells overnight, was used to label lysosomes in combination with 
LysoSensor DND-160 for selectivity of lysosomal labeling. Light emitted at 520 
nm in response to excitation at 340 nm and 380 nm was measured for 2 msec 
every 10 seconds using a filter-based imaging system (Zeiss, Germany). The 
ratios of light excited (340/380 nm) versus light emitted (520 nm) were converted 
to pH using a calibration curve established with 10 µM of the H+/Na+ ionophore 
monensin, and 20 µM of the H+/K+ ionophore nigericin; both were dissolved in 20 
mM 2-(N-morpholino) ethane sulfonic acid (MES), 110 mM KCl, and 20 mM NaCl 
adjusted to pH 3.0 to 7.0 with HCl/NaOH; the linear range was found to be 4.5 to 
6.0 pH. 
Endolysosome Iron 
 FeRhonox-1 (10 µM) (Goryo Chemical), which is highly specific for Fe2+, 
was incubated with cells for 1 h, washed with PBS, then measured using a 
confocal microscope at absorption and emission wavelengths 537 nm and 569 
nm, respectively. As reported elsewhere (see Chapter 2), FeRhonox-1 staining 
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colocalized with endolysosomes in U87MG cells and primary cultures of rat 
cortical neurons. Experiments were conducted on a LSM800 confocal laser-
scanning microscope (ZEISS). 
Cytosolic Iron 
 Cells were incubated with PhenGreen™ FL diacetate (10 µM) for 
30 minutes at 37oC. Cells were washed with PBS and analyzed (Alexa Fluor 488) 
using a ThermoFisher Attune flow cytometry and an Axiovert 200M (Zeiss) 
microscope. Alexa Fluor 488 is absorbed at 495 nm and emitted at 519 nm. The 
x-mean value of emission was recorded on flow cytometry. 
Mitochondrial Iron 
 Mitochondrial iron levels were measured using rhodamine  
B-[2,2'-bipyridine-4-yl)-aminocarbonyl]benzyl ester (RDA) dye (Squarix), a  
Fe2+ specific fluorescent sensor that is localized within mitochondria. Cells were 
treated with RDA (100 nM) for 10 minutes at 37°C, then washed with PBS 
followed by experiments conducted on a confocal laser scanning microscope 
(ZEISS). RDA absorbance is 562 nm and emission is 598 nm. Fluorescent 
intensity was measured across 30 mitochondria per cell per individual treatments 
for control cells and drug treated cells. The change in fluorescence for control 
cells was insignificant compared to chloroquine and bafilomycin A1 treated cells. 
Iron Chelation 
 Deferoxamine (50 µM), a Fe2+ chelator that is endocytosed (Doulias et al., 
2003), was incubated in cells for 1 h prior to analysis and administering other 
compounds. It is known that DFO does not enter cells by passive diffusion, that it 
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does enter cells by endocytosis, and that following endocytosis it resides in 
endolysosomes for extended periods of time (Lloyd et al., 1991). This make DFO 
a particular useful agent to determine roles for endolysosome Fe2+.  
ROS Measurements 
 Cytosolic ROS was measured using H2DCFDA,  
2,7-dichlorodihydrofluoroscein diacetate (10 µM) (Thermofisher), and 
mitochondrial ROS was measured using MitoSox Red (5 µM) (Thermofisher). 
Cells were incubated with the respective dyes at 37ºC for 30 minutes in serum 
free media and then washed with PBS prior to analysis by flow cytometry.  
Generation of TPCN2-Knock Down U87MG Cells 
 In U87MG cells, expression levels of TPCN2 channels were knocked 
down using 1 μg/ml shRNA (Santa Cruz) against TPCN2 (Sc-); scrambled 
shRNA (Sc-108060) was used as a control. Jet prime reagent (2 μl) was used for 
transfection. Following 36 h incubation, 25 μg/ml puromycin (Invitrogen) was 
added to activate the shRNA promoter. After incubation for 2 to 3 days, cells 
were passaged to remove the dead and dying cells; the remaining living cells 
were cultured for an additional 36 h prior to being taken for experimentation. 
Knockdown efficiency was confirmed by immunoblotting using antibodies against 
TPCN2 (Novus, NBP1-30670).  
Cell Death Measurements 
 Cell death was measured using 20 ug/ml of propidium iodide (PI) staining 
(Sigma-Aldrich). Cells were treated with the various compounds for 24 h, then 
incubated with propidium iodide for 30 minutes, washed with PBS, and then 
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measurements were acquired by flow cytometry (Attune NxT). The positive 
control was methanol (10 µM) incubated for 2 hours. PI excitation/emission is 
493 nm/636 nm. Cells treated with only PI were gated on flow cytometry and 
used as a baseline for sample treated cells. 
Statistical Analysis 
 All results are expressed as mean ± SD. Data were analyzed using 
GraphPad Prism Version 6 (GraphPad Software, Inc., La Jolla, CA). Statistical 
significance between two groups was analyzed with a Student’s t-test, and 
statistical significance among multiple groups was analyzed with one-way 
ANOVA plus a Tukey post-hoc test. p<0.05 was considered to be statistically 
significant. 
Results 
 Bafilomycin A1 and chloroquine de-acidify endolysosome pH: 
Cultured U87MG cells were incubated with CellLight Lysosome-RFP and 
Lysosensor DND-160, which is a ratiometric excitation dye that allows for the 
measurement of acidic organelles. Cells were treated with bafilomycin A1 (80 nM 
and 200 nM) and chloroquine (100 µM and 200 µM). Bafilomycin A1 is a known 
inhibitor of vacuolar-ATPase and chloroquine is a weak base; both are known to 
increase the pH of endolysosomes (Tapper and Sundler, 1995, Steinman et al., 
1983). Bafilomycin A1 and chloroquine de-acidified endolysosomes within 
seconds of being added to cells as shown in Figure 3.1A. In addition, the de-
acidification of endolysosomes by bafilomycin A1 and chloroquine was dose-
dependent (Figure 3.1B). Furthermore, cells were stained with Lysosensor  
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DND-189; an alternate method for measuring endolysosome pH. As with DND-
160, bafilomycin A1 and chloroquine de-acidified endolysosome pH as 
determined using DND-189, time-dependently (Figure 3.1C). For ease of 
illustration, data were represented as a reciprocal of the mean fluorescent 
intensity so that the increases in pH were readily apparent.  
Bafilomycin A1 and Chloroquine Release Fe2+ from  
Endolysosomes into the Cytosol 
 The FeRhonox-1 dye was previously determined to be highly specific for 
Fe2+ and endolysosomes (see Chapter 2). In addition, it has been shown that the 
iron chelator DFO inhibits FeRhonox-1 fluorescent intensity because it is 
endocytosed and chelates Fe2+ (see Chapter 2). U87MG cells were co-stained 
with FeRhonox-1 and LysoTracker for 1 h prior to experimentation. The dual dye 
method was used to ensure measurement of endolysosome iron as well as to be 
more indicative of iron release from endolysosomes rather than just an efflux of 
the FeRhonox-1 dye from non-descript sources. Therefore, the FeRhoNox-
1/LysoTracker ratio was used as a method of analysis. In addition, these 
experiments were conducted at times ranging from 0 to 10 min; intervals that are 
consistent with time intervals for de-acidification of endolysosomes by 
bafilomycin A1 and chloroquine (Figure 3.1). FeRhonox-1 colocalized with 
LysoTracker with a Pearson Correlation Coefficient of 0.84 (Figure 3.2A) as 
previously determined (see Chapter 2). In control cells treated with PBS, the 
FeRhonox-1/LysoTracker ratio did not change significantly (Figure 3.2B). 
Chloroquine significantly decreased (**P < 0.001) the FeRhonox-1/LysoTracker 
from 1.0 to 0.91 (Figure 3.2C). Quantification of the FeRhonox-1/LysoTracker 
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ratios within endolysosomes for control and chloroquine treated cells is shown in 
Figure 3.2D, and the quantification of the cytosolic FeRhonox-1/LysoTracker ratio 
for control and chloroquine treated cells is shown in Figure 3.2E. Similar 
experiments were conducted with bafilomycin A1. In control cells treated with 
0.1% DMSO the FeRhonox-1/LysoTracker ratio was not affected significantly 
(Figure 3.3A). However, bafilomycin A1 significantly decreased (**P < 0.001) the 
FeRhonox-1/LysoTracker from 1.0 to 0.89 (Figure 3.3B). Quantification of the 
FeRhonox-1/LysoTracker ratio within endolysosomes for control and bafilomycin 
A1 treated cells is shown in Figure 3.3C, and the quantification of the cytosolic 
FeRhonox-1/LysoTracker ratio for control and bafilomycin A1 treated cells is 
shown in Figure 3.3D. 
 To determine whether iron was released into the cytosol, Phen-Green FL 
was used; a dye whose fluoresence quenches in the presence of metals such as 
zinc, copper, and ferrous iron. Because Phen Green is a quenching stain, the 
reciprocal of the mean fluorescent intensity was calculated to illustrate more 
easily de-acidification induced increase in cytosolic iron. Deferoxamine is a 
ferrous iron chelator that is endocytosed (Doulias et al., 2003), and DFO 
significantly decreased the quenching of Phen-Green, indicating there is a 
constitutive leak of Fe2+ from endolysosomes into the cytosol as shown in 
Figure 4. Bafilomycin A1 and chloroquine significantly quenched Phen-Green. 
Pretreatment with DFO, prior to bafilomycin A1 and chloroquine treatment, 
blocked the quenching of Phen-Green, indicating a release of Fe2+ from 
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endolysosomes into the cytosol by bafilomycin A1 and chloroquine as shown in 
Figure 3.4 by flow cytometry.  
Endolysosome Iron is Taken up by Mitochondria 
 Rhodamine B 4-[(2,2'-bipyridin-4-yl)aminocarbonyl]benzyl ester (RDA) is a 
dye specific to Fe2+ and the mitochondria, and RDA fluorescence is 
stoichiometrically (3:1) quenched by Fe2+ ions (Rauen et al., 2007). U87MG cells 
were stained with RDA (100 nM) and MitoTracker (10 µM); the two dyes 
colocalized with a Pearson Correlation Coefficient of 0.97 as shown in 
Figure 3.5A. The following RDA experiments were conducted using incubation 
intervals ranging from 0 to 10 min; a time frame consistent with de-acidification of 
endolysosomes by bafilomycin A1 and chloroquine (Figure 3.1) and the release 
of Fe2+ from endolysosomes (Figures 3.2 and 3.3). Control cells treated with PBS 
and DMSO which did not yield significant changes to RDA fluorescence (Figure 
3.5B), and DFO did not significantly change the fluorescence intensity of RDA 
(Figure 3.5C). Bafilomycin A1 and chloroquine quenched RDA fluorescence as 
shown in Figure 3.5D and 3.5F, and DFO pretreatment blocked RDA quenching 
induced by bafilomycin A1 and chloroquine treatment (Figure 3.5E and 3.5G). 
These data indicate that endolysosome iron was translocated to mitochondria. 
Quantification of these mitochondrial iron experiments is shown in Figure 3.5H. 
An increase in mitochondrial iron was dose-dependent for bafilomycin A1 and 
chloroquine (Figure 3.5I and 3.5J) as were changes in endolysosome pH 
(Figure 3.1). The compound dipeptide glycyl-l-phenylalanine 2-naphthylamide 
(GPN) is a lysosomotropic agent that disrupts endolysosome membranes and 
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releases contents of endolysosomes into the cytosol (Berg et al., 1994); as such 
GPN was used to induce non-selectively the release of Fe2+ from 
endolysosomes. GPN quenched RDA in a dose-dependent manner as shown in 
Figure 3.5K. These data taken together demonstrate inter-organellar signaling of 
Fe2+ from endolysosomes to mitochondria.  
Bafilomycin A1 and Chloroquine-Induced Fe2+ Release from 
Endolysosomes Increases Cytosolic ROS and Mitochondrial ROS 
 Ferrous iron is a key reactant in the formation of the highly reactive 
hydroxyl and superoxide radicals (Fenton, 1894). U87MG cells were stained with 
2′,7′-dichlorofluorescin diacetate (H2DCFDA), which is a measure of cytosolic 
ROS. Bafilomycin A1 and chloroquine both increased cytosolic ROS, and DFO 
blocked bafilomycin and chloroquine-induced increases in cytosolic ROS 
(Figure 3.6A). U87MG cells were stained with MitoSox, a mitochondrial measure 
of ROS. Bafilomycin A1 and chloroquine both increased mitochondrial ROS, and 
DFO blocked bafilomycin and chloroquine-induced increases in mitochondrial 
ROS (Figure 3.6B).  
Two-pore Channels are Involved in Fe2+ Release from Endolysosomes 
 Two-pore channels have been shown to be involved in the release of 
divalent cations including calcium from endolysosomes (Rivero-Rios et al., 2016). 
Therefore, TPCs were analyzed as an endolysosome channel for Fe2+ release. 
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a TPC activator 
(Boccaccio et al., 2014), and NED-19 is a known inhibitor of TPCs (Zharkich et 
al., 2016). U87MG cells were stained with RDA and treated with NAADP-AM, 
which caused a dose-dependent increase in mitochondrial iron as shown in 
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Figure 3.7A. Pretreatment with NED-19 for 30 minutes significantly reduced 
mitochondrial iron uptake induced by chloroquine or bafilomycin A1 treatment 
(Figure 3.7B and 3.7C). TPCN2 knockdown cells (Figure 3.7D) significantly 
reduced mitochondrial iron uptake (Figure 3.7B and 3.7C).  
Mitochondrial Permeability Transition Pores (MPTPs) Uptake Fe2+  
into the Mitochondria 
 Mitochondrial permeability transition pores are known to regulate 
mitochondrial iron (Sripetchwandee et al., 2014), and auranofin is a known 
activator of MPTPs (Rigobello et al., 2002). Cyclosporin A and TRO19622 inhibit 
MPTP (Sripetchwandee et al., 2014, Bordet et al., 2010). GPN (1 µM) plus 
auranofin (1 µM) increased mitochondrial uptake of iron, and CSA and 
TRO19622 blocked mitochondrial iron uptake (Figure 3.8A). As for GPN, similar 
findings were found with bafilomycin A1 and chloroquine as shown in Figure 3.8B 
and 3.8C.  
Deferoxamine Protects Cells from Chloroquine and Bafilomycin  
A1-Induced Cell Death 
 U87MG cells were treated with chloroquine and bafilomycin A1 for 24 h, 
stained with propidium iodide (PI) (20 ug/ml), and analyzed for cell death using 
flow cytometry. The positive control for cell death was cells treated with methanol 
(10 µM) for 2 h. In addition, cells were pretreated with DFO (50 µM) for 1 hr prior 
to chloroquine and bafilomycin A1 treatment. Chloroquine and bafilomycin A1 
induced cell death after 24 h and DFO protected cells from chloroquine- and 
bafilomycin A1-induced cell death (Figure 3.9).  
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Schematic Diagram of Overall Cellular Mechanisms 
 The schematic diagram of the proposed involved cellular mechanisms is 
illustrated in Figure 3.10. According to this scheme, chloroquine and bafilomycin 
A1 de-acidification of endolysosomes causes the release of iron from 
endolysosomes into the cytosol where it can be up-taken by mitochondria. The 
iron released from endolysosomes leads to increased ROS in the cytosol and in 
mitochondria. DFO chelates endolysosome iron and inhibits levels of ROS 
induced by chloroquine and bafilomycin A1 as well as cell death. 
Discussion 
 Intracellular labile iron has key roles in many physiological functions and 
excess levels of intracellular Fe2+ have been implicated in the pathogenesis of 
cancer and neurodegenerative diseases (Padmanabhan et al., 2015, Rockfield et 
al., 2017). Disrupted iron homeostasis may be an important factor in disease 
initiation and progression (Enns, 2003, Jellinger, 2009) and it is well-known that 
endolysosomes are storage sites for readily-releasable redox-active Fe2+ cations 
(Xu and Ren, 2015, Xiong and Zhu, 2016b). However, due at least in part to the 
lack of available probes with which to study endolysosome Fe2+, it has been 
difficult to determine the degree to which and the mechanisms by which 
endolysosome Fe2+ affects such physiologically and pathologically relevant 




 In agreement with previous studies by others and us, we demonstrated 
that chloroquine and bafilomycin A1 de-acidified endolysosomes (Yoshimori et 
al., 1991) (Steinman et al., 1983), and de-acidification is known to cause an 
efflux of Ca2+ into the cytosol (Christensen et al., 2002, Fernández et al., 2016b, 
Xiong and Zhu, 2016b, Hui et al., 2015). Using the FeRhonox-1 probe, we 
demonstrated that bafilomycin A1 and chloroquine decreased levels of Fe2+ in 
endolysosomes.  
 To determine if the deacidification-induced decreases in endolysosome 
Fe2+ resulted in increases in the cytosol, we used Phen Green Diacetate, which 
is a cell permeant dye that quenches when exposed to ions including Cu2+, Fe2+, 
Pb2+, Cd2+, Zn2+ and Ni2+. However, a study has shown using external metals 
that only Fe2+ and Cu2+ produced significant fluorescent quenching of Phen 
Green, and the other metals produced very little change in dye fluorescence 
(Chavez-Crooker et al., 2001). Furthermore, previous studies have used calcein 
as a measurement of Fe2+ (Uchiyama et al., 2008), but recent studies have 
shown that calcein binds Fe3+ and not Fe2+ (Thomas et al., 1999). We 
demonstrated that bafilomycin A1 and chloroquine quenched Phen-Green, and 
even though Cu2+ can quench Phen-Green, the quenching induced by 
chloroquine and bafilomycin A1 was prevented by pretreatment with DFO, which 
is highly specific for iron and not copper (Liu and Hider, 2002). Thus, Phen Green 
quenching is most likely from an increase in chelatable ferrous iron. Interestingly, 
pretreatment of DFO increased PhenGreen fluorescence which indicates a 
constitutive leak of Fe2+ from endolysosomes into the cytosol.  
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 Rhodamine B 4-[(2,2'-bipyridin-4-yl)aminocarbonyl]benzyl ester (RDA) is a 
dye specific for Fe2+ and mitochondria, and RDA fluorescence is 
stoichiometrically (3:1) quenched by Fe2+ (Rauen et al., 2007). We confirmed this 
with RDA and MitoTracker, which colocalized with a Pearson Correlation 
Coefficient of 0.97. After chloroquine and bafilomycin A1 treatment, RDA 
fluorescence quenched, which signifies an increase of chelatable ferrous iron 
within the mitochondria. Moreover, DFO pretreatment suppressed mitochondrial 
RDA quenching after chloroquine and bafilomycin A1 treatment. Thus, Fe2+ 
released from endolysosomes into the cytosol by chloroquine and bafilomycin A1 
was being taken up by mitochondria. These findings suggest that there is inter-
organellar signaling of the ferrous iron cation between endolysosomes and 
mitochondria. 
 In the presence of H2O2 and O2, Fe2+ catalyzes hydroxyl radicals and 
superoxides (Fenton, 1894), and the presence of H2O2 and O2 in the cytosol and 
mitochondria is well studied (Halliwell et al., 2000, Veal et al., 2007). After 
chloroquine and bafilomycin A1 treatment, cytosolic ROS and mitochondrial ROS 
significantly increased; findings that suggest that ferrous iron catalyzed ROS 
formation. Furthermore, DFO blocked bafilomycin and chloroquine-induced 
cytosolic and mitochondrial ROS. These findings indicate that endolysosome 
ferrous iron is responsible for ROS production in the cytosol and mitochondria.  
Two-pore channels have been shown to be involved in the release of 
calcium from endolysosomes (Rivero-Rios et al., 2016). Therefore, we studied 
the possible involvement of TPCN2 in the release of Fe2+ from endolysosomes. 
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Nicotinic acid adenine dinucleotide phosphate (NAADP) a TPC activator 
(Boccaccio et al., 2014) caused a dose-dependent increase in mitochondrial iron. 
On the other hand, NED-19 a known inhibitor of TPCs (Zharkich et al., 2016) 
significantly decreased mitochondrial iron uptake induced by chloroquine or 
bafilomycin A1. Furthermore, knocking down expression levels of TPCN2 
significantly reduced mitochondrial iron uptake, which is consistent with the NED-
19 experiments. 
 Mitochondrial permeability transition pores are known to regulate levels of 
mitochondrial iron (Sripetchwandee et al., 2014). Auranofin is a known activator 
of mPTPs ((Rigobello et al., 2002) and we showed that auranofin increased 
mitochondrial uptake of iron. On the other hand, cyclosporin A and TRO19622 
both inhibit mPTPs (Sripetchwandee et al., 2014, Bordet et al., 2010) and we 
found that CSA and TRO19622 blocked mitochondrial iron uptake.  
 Lastly, chloroquine (100 µM) and bafilomycin A1 (200 nM) treatment 
induced cell death after 24 h, and DFO protected cells against chloroquine- and 
bafilomycin A1-induced cell death. These findings are consistent with chloroquine 
and bafilomycin A1 inducing mitochondrial iron overload leading to increased 
ROS production which irreversibly damages the cells to the point of cell death. 
DFO prevented mitochondrial iron overload induced by chloroquine and 
bafilomycin A1 and thereby protected cells against the induced cytotoxicity.  
 In conclusion, excess iron is a known toxicant that can lead to acute 
cellular injury (Christ et al., 1995), and excess iron may promote diseases such 
as diabetes, cancer, cardiovascular disease, and neurodegeneration (Swanson, 
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2003, Petersen, 2005, Brewer, 2007, Imeryuz et al., 2007). With recent studies 
showing there is more ferrous iron in endolysosomes than previously thought 
(see Chapter 2), it is important to determine the role of endolysosome iron in 
cellular functions. This study reveals that Fe2+ stored in endolysosomes is 
mobilized into the cytosol and mitochondria following endolysosome 
deacidification and that this can ultimately lead to mitochondrial dysfunction and 
cell death. These data support the idea that mitochondrial iron accumulation is 
downstream of changes to endolysosomes. Thus, possible treatments against 




Figure 3. 1  Chloroquine and bafilomycin A1 de-acidified endolysosomes:  
(A) Chloroquine and bafilomycin A1 increased endolysosome pH 
as measured using LysoSensor DND-160.  
(B) Treatment with different concentrations of bafilomycin A1 and 
chloroquine resulted in an increase in endolysosome pH.  
(C) Using Lysosensor DND-189, bafilomycin A1 and chloroquine 
de-acidified endolysosomes in a time-dependent manner as 
shown here using the reciprocal of 1 to illustrate an increase in 
pH.  
(Vehicle for bafilomycin A1 was 0.1% DMSO and vehicle for CQ 
was PBS. n=30; ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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Figure 3. 2.  Chloroquine reduced Fe2+ levels in endolysosomes:  
(A) FeRhoNox-1 colocalized with LysoTracker with a Pearson 
Correlation Coefficient of 0.84.  
(B) Control treatment with PBS did not significantly change 
fluorescent intensity.  
(C) Treatment with chloroquine (100 µM) resulted in a significant 
decrease in FeRhoNox-1 fluorescence intensity at 10 minutes. 
(D) Quantification of FeRhoNox-1/Lysotracker ratio in 
endolysosomes.  
(E). Quantification of FeRhoNox-1/Lysotracker ratio in the 
cytosol. FeRhoNox-1 fluorescence intensity decreased faster 
than LysoTracker fluorescence intensity in endolysosomes upon 
treatment, which is indicative of a reduction of iron. 





Figure 3. 3.  Bafilomycin A1 reduced Fe2+ levels in endolysosomes:  
(A) Treatment of U87MG cells with vehicle (DMSO 0.1%) did not 
significantly change fluorescence intensity.  
(B) Treatment with bafilomycin A1 (200 nM) resulted in a 
significant decrease in FeRhoNox-1 fluorescence intensity.  
(C) Quantification of FeRhoNox-1/Lysotracker ratios in 
endolysosomes.  
(D) Quantification of FeRhonox-1/Lysotracker ratios in the 
cytosol. FeRhoNox-1 fluorescence intensity is decreasing faster 
than LysoTracker fluorescent intensity in endolysosomes upon 
treatment, which is indicative of a reduction in iron content. 






Figure 3. 4.  Chloroquine and bafilomycin A1 increased cytosolic Fe2+: 
Chloroquine (100 µM) and bafilomycin A1 (200 nM) quenched 
Phen-Green; data were illustrated as a reciprocal of the Mean 
Fluorescent Intensity (MFI) to illustrate more clearly the increase 
in cytosolic iron. DFO blocked chloroquine and bafilomycin  
A1-induced quenching of Phen-Green. DFO alone suppressed 
Phen-Green quenching a finding that suggests the presence of a 
constitutive leak of Fe2+.  
(n=5; ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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Figure 3. 5.  Chloroquine and bafilomycin A1 increased mitochondrial Fe2+: 
(A) Colocalization of the mitochondrial iron stain (RDA) and 
MitoTracker with a Pearson Correlation Coefficient of 0.97.  
(B) Control cells stained with RDA treated with PBS (DMSO 
yielded similar results as PBS).  
(C) DFO (100 µM) did not alter fluorescence intensity.  
(D-G) Chloroquine (100 µM) and bafilomycin A1 (200 nM) 
quenched RDA fluorescence and DFO blocked chloroquine and 
bafilomycin A1-induced quenching as quantified in (H).  
(I-K) Mitochondrial iron uptake is dose-dependent on GPN, 
chloroquine, and bafilomycin A1.  






Figure 3. 6.  Chloroquine and bafilomycin A1 increased cytosolic ROS and 
mitochondrial ROS:  
(A) Using H2DCFDA for measures of cytosolic ROS, chloroquine 
(100 µM) and bafilomycin A1 (200 nM) increased ROS, and 
these increases were inhibited by DFO.  
(B) Using MitoSox for measures of mitochondrial ROS, 
chloroquine (100 µM) and bafilomycin A1 (200 nM) increased 
ROS, and these increases were inhibited by DFO. 
(n=5; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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Figure 3. 7.  Mitochondrial iron uptake was regulated by two-pore channels 
on endolysosomes:  
(A) The TPC activator, NAADP-AM, dose-dependently increased 
mitochondrial iron.  
(B-C) The TPC antagonist, NED-19, dose-dependently blocked 
mitochondrial iron uptake induced by chloroquine (100 µM) and 
bafilomycin A1 (200 nM).  
(D) TPCN2 knockdown cells significantly decreased 
mitochondrial iron uptake induced by bafilomycin A1 and 
chloroquine.  
(E) Interestingly, NAADP-AM (20 µM) significantly de-acidifies 
endolysosomes whereas NED-19 remains unchanged.  




Figure 3. 8.  Mitochondrial permeability transition pores (mMPTP) regulated 
iron uptake:  
(A) Auranofin (AF) increased GPN-induced mitochondrial iron 
uptake, and cyclosporine A (CSA) in combination with 
TRO19622 (TRO) inhibited GPN-induced mitochondrial iron 
uptake.  
(B-C) AF increased chloroquine- and bafilomycin A1-induced 
mitochondrial iron uptake, and CSA and TRO inhibited 
mitochondrial iron uptake.  




Figure 3. 9.  Deferoxamine protected against chloroquine- and bafilomycin 
A1-induced cell death:  
(A) Histogram of cell death experiment with propidium iodide. 
Methanol (10 µM) caused 80% cell death after 2 h and was used 
as a positive control.  
(B) Chloroquine (100 µM) and bafilomycin A1 (200 nM) 
increased cell death after 24 hours, and DFO pretreatment 
protected cells against chloroquine- and bafilomycin A1-induced 
cell death.  





Figure 3. 10.  Schematic diagram of cellular mechanisms: De-acidification of 
endolysosomes can cause the release of iron from 
endolysosomes and this released iron can accumulate in the 
cytoplasm and in mitochondria. The iron released from 
endolysosomes leads to increased levels of ROS in the cytosol 
and in mitochondria. DFO chelates endolysosome iron and 
inhibits ROS and cell death induced by chloroquine and 
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 Drugs of abuse including the opioid morphine increase levels of reactive 
oxygen species (ROS) and predispose cells to insult-induced cell death. 
However, it remains uncertain as to the underlying mechanisms. Iron has long 
been known to be required for the generation of mitochondrial ROS and 
endosomes and lysosomes, referred to as endolysosomes, are major storage 
sites of ferrous iron (Fe2+). Yet, the degree to which and the precise mechanisms 
by which endolysosome iron plays a role in mitochondrial dysfunction remains 
uncertain. Here, our studies were aimed to determine the effects of morphine on 
inter-organellar signaling of Fe2+ from iron-rich endolysosomes to mitochondria. 
We demonstrated, in U87MG astrocytoma cells, that endolysosome Fe2+ is 
translocated to mitochondria and results in mitochondrial dysfunction. Morphine 
de-acidification of endolysosomes caused the release of Fe2+ from 
endolysosomes and increased levels of Fe2+ in cytosol and in. The morphine-
induced effects on endolysosome Fe2+ appeared to be regulated through mu 
opioid receptors because naloxone blocked the de-acidification of 
endolysosomes by morphine and the release of endolysosome iron. 
Furthermore, the endocytosed iron chelator, deferoxamine, inhibited the release 
of redox-active Fe2+ into the cytosol and the morphine-induced increases in 
mitochondrial ROS. These findings demonstrate that redox-active Fe2+ in 
endolysosomes plays a key upstream role in mitochondrial dysfunction, and 
deferoxamine might be a potentially useful therapeutic strategy associated with 
opioid use disorders.  
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Introduction 
 Drugs of abuse including the opioid morphine have been associated with 
the pathogenesis of neurological diseases; mechanistically this had been linked 
through increases in reactive oxygen species (ROS), mitochondrial dysfunction, 
and bioenergetic failure (Imam and Ali, 2000, Imam and Ali, 2001, Stephans et 
al., 1998, Cunha-Oliveira et al., 2013, Xu et al., 2011). Drugs of abuse-induced 
decreases in levels of ATP and increased levels of ROS (Acikgoz et al., 1998, 
Binienda et al., 1998) and such measures of neurotoxicity can be blocked by the 
antioxidants (Fosslien, 2001, Imam and Ali, 2000). However, mechanisms by 
which opioids (and other drugs of abuse) increase levels of ROS remain unclear.  
 Iron plays a crucial role in cellular functions such as the iron-sulfur clusters 
in the electron transport chain and iron in excess is toxic and leads to cellular 
injury and death (Christ et al., 1995). Excess iron can promote 
neurodegeneration (Swanson, 2003, Petersen, 2005, Brewer, 2007, Imeryuz et 
al., 2007) and iron dyshomeostasis has been linked to disease initiation and 
progression (Enns, 2003, Jellinger, 2009). Even though various models of 
oxidative stress and hypoxia have pointed to a role for iron in their pathogenesis 
(Jellinger, 2009), the intracellular source of excess iron and the precise 
mechanisms by which iron is mobilized intracellularly to contribute to cellular 
injury remain poorly understood. 
 A key reactant in the formation of ROS is ferrous iron (Fe2+) (Fenton, 
1894, Kehrer, 2000, Weiss, 1934). In the presence of H2O2 and O2, Fe2+ 
generates highly reactive hydroxyl radicals (HO) and superoxides (O2-) that 
76 
ultimately damage DNA and proteins (Kehrer, 2000). It is well established that 
ROS contributes to cellular dysfunction and cell death (Jaeschke et al., 2002, 
Videla et al., 2003, Schwabe and Brenner, 2006). Furthermore, the most 
important source of ROS happens in the mitochondria because that is where 
ATP is produced (Loschen et al., 1974, Boveris and Cadenas, 1975). Because 
mitochondria have a constitutive presence of ROS generated by the electron 
transport chain, the levels of mitochondrial iron must be tightly regulated. The 
accumulation of iron in the mitochondria has been observed in neurogenerative 
diseases, but the source of excess iron and how mitochondrial iron accumulation 
is a downstream effect remains undetermined (Mena et al., 2015).  
 Endosomes and lysosomes, referred to as endolysosomes, have key 
physiological roles including plasma membrane repair, cell homeostasis, cell 
adhesion and migration, apoptotic cell death, and metabolic signaling (Perera 
and Zoncu, 2016, Settembre et al., 2013). And, it is well-established that 
endolysosomes store readily-releasable cations including Ca2+, Zn2+, Fe3+, and 
Fe2+ (Xu and Ren, 2015, Xiong and Zhu, 2016b). The acidic pH of endolysosome 
lumens is maintained through the influx of protons via v-ATPases in conjunction 
with ion channels (TRPML1, TPCs, and BK) regulating cation concentrations 
within endolysosomes (Pu et al., 2016). The v-ATPase mechanism generates a 
proton force that drives ions across endolysosome membranes creating a 
voltage gradient which is sustained by counter-ions including Na+, K+, and Cl- 
(Mindell, 2012a). The efflux of cations such as Ca2+ from endolysosomes into the 
cytosol has been demonstrated with drugs that de-acidify endolysosomes, and 
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these released cations play crucial roles in cellular signaling pathways 
(Christensen et al., 2002). However, very little is known about the role of the 
redox-active Fe2+ cation within endolysosomes in inter-organellar signaling and 
cell death. 
 In this study, we show morphine de-acidifies endolysosomes causing an 
efflux of Fe2+ out of endolysosomes into the cytosol and into mitochondria 
increasing. As well, morphine increased levels of ROS and these effects of 
morphine were controlled by mu opioid receptors because naloxone blocked 
morphine-induced de-acidification of endolysosomes and morphine-induced 
release of iron from endolysosomes. In addition, we demonstrate that the iron 
chelator DFO blocked morphine-induced increases in cytosolic and mitochondrial 
Fe2+ as well as morphine-induced increases in mitochondrial ROS. These studies 
emphasize the link between opioids and endolysosomes as intracellular sources 
of iron that translocate into mitochondria leading to increased ROS and 
dysfunction. 
Materials and Methods 
Cell Culture 
 U87MG astrocytoma cells were cultured in 1x DMEM (Invitrogen) 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin 
(Invitrogen). Cells were grown to confluence in T75 flasks or to about 
40% confluence in 35 mm2 dishes in an environment of 5% CO2 at 37oC. Cells 




 As previously described (Chen et al., 2013, Hui et al., 2012a, Hui et al., 
2012b), endolysosome pH was measured using a ratiometric indicator-dye, 
LysoSensor Yellow/Blue DND-160; a dual excitation dye that allows for the 
measurement of acidic organelles independent of dye loading efficiency. U87MG 
cells were loaded with 10 µM DND-160 for 5 minutes at 37°C. Post-incubation, 
dye-containing media was removed and PBS was added to the cells prior to 
them being taken for imaging. CellLight Lysosome-RFP (Thermosfisher), 
incubated in cells overnight, was used to label lysosomes in combination with 
LysoSensor DND-160 for selectivity of lysosomal labeling. Light emitted at 
520 nm in response to excitation at 340 nm and 380 nm was measured for 
2 msec every 10 seconds using a filter-based imaging system (Zeiss, Germany). 
The ratios of light excited (340/380 nm) versus light emitted (520 nm) were 
converted to pH using a calibration curve established with 10 µM of the H+/Na+ 
ionophore monensin, and 20 µM of the H+/K+ ionophore nigericin; both were 
dissolved in 20 mM 2-(N-morpholino) ethane sulfonic acid (MES), 110 mM KCl, 
and 20 mM NaCl adjusted to pH 3.0 to 7.0 with HCl/NaOH; the linear range was 
4.5 to 6.0 pH. 
Endolysosome Iron 
 FeRhonox-1 (10 µM) (Goryo Chemical), which is highly specific for Fe2+, 
was incubated with cells for 1 h, washed with PBS, then measured using a 
confocal microscope at absorption and emission wavelengths 537 nm and 569 
nm, respectively. Halcrow et el. (see Chapter 2) colocalized FeRhonox-1 with 
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endolysosomes in U87MG cells and primary neurons. Experiments were 
conducted on a LSM800 confocal laser-scanning microscope (ZEISS). 
Cytosolic Iron 
 Cells were incubated with PhenGreen™ FL diacetate (10 µM) for 
30 minutes at 37oC. Cells were washed with PBS and analyzed (Alexa Fluor 488) 
using a ThermoFisher Attune flow cytometry and an Axiovert 200M (Zeiss) 
microscope. 
Mitochondrial Iron 
 Mitochondrial iron levels were measured using rhodamine  
B-[2,2'-bipyridine-4-yl)-aminocarbonyl]benzyl ester (RDA) dye (Squarix), a Fe2+ 
specific fluorescent sensor that is localized within mitochondria. Cells were 
treated with RDA (100 nM) for 10 minutes at 37°C, then washed with PBS 
followed by experiments conducted on a confocal laser scanning microscope 
(ZEISS).  
Iron Chelator 
 Deferoxamine (50 µM), a Fe2+ chelator that is endocytosed (Doulias et al., 
2003), was incubated in cells for 1 h prior to analysis and administering other 
compounds.  
ROS Measurements 
 Cytosolic ROS was measured using H2DCFDA,  
2,7-dichlorodihydrofluoroscein diacetate (10 µM) (Thermofisher), and 
mitochondrial ROS was measured using MitoSox Red (5 µM) (Thermofisher). 
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Cells were incubated with the respective dyes at 37ºC for 30 minutes in serum-
free media and then washed with PBS prior to analysis by flow cytometry. 
Statistical Analysis 
 All results were expressed as mean ± SD. Data were analyzed using the 
software GraphPad Prism Version 6 (GraphPad Software, Inc., La Jolla, CA). 
Statistical significance between two groups was analyzed with a Student’s t-test, 
and statistical significance among multiple groups was analyzed with one-way 
ANOVA plus a Tukey post-hoc test. p<0.05 was considered to be statistically 
significant. 
Results 
Morphine De-acidified Endolysosome pH 
 Cultured U87MG cells were incubated with CellLight Lysosome-RFP and 
Lysosensor DND-160, which is a ratiometric excitation dye that allows for the 
measurement of pH in acidic organelles. Cells were treated with different 
concentrations of morphine (1 µM, 50 µM, and 100 µM). Morphine (10 µM) de-
acidification of endolysosomes is a delayed response as shown in Figure 4.1A. 
Naloxone, a mu opioid antagonist, which did not by itself change endolysosome 
pH blocked the de-acidification of endolysosomes by morphine as shown in 
Figure 4.1B. In addition, the de-acidification of endolysosomes by morphine was 
dose-dependent (Figure 4.1C).  
Morphine Releases Fe2+ from Endolysosomes into the Cytosol 
 The FeRhoNox-1 dye was previously determined to be highly specific for 
Fe2+ and endolysosomes (see Chapter 2). In addition, it has been shown that the 
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iron chelator DFO inhibits FeRhoNox-1 fluorescent intensity because it is 
endocytosed and chelates Fe2+ (see Chapter 2). U87MG cells were stained with 
FeRhoNox-1 for 1 h prior to experimentation. Also, these experiments were 
conducted from 0 min to 30 min, times consistent with rates of endolysosome de-
acidification by morphine (Figure 4.1). In control cells treated with PBS, 
FeRhoNox-1 fluorescence intensity did not significantly change (Figure 4.2). 
Morphine significantly decreased FeRhoNox-1 fluorescence intensity, and 
naloxone inhibited the effects of morphine. Quantification of the FeRhoNox-1 
within endolysosomes for control and morphine treated cells is shown in 
Figure 4.2D. To determine whether iron was released into the cytosol, Phen-
Green FL was used; Phen-Green is a dye that quenches in the presence of 
metals such as zinc, copper, and ferrous iron. Because Phen-Green is a 
quenching stain, the reciprocal of the mean fluorescent intensity was calculated 
to illustrate an increase in cytosolic iron. Morphine treatment significantly 
quenched Phen Green, and naloxone blocked morphine-induced effects as 
shown in Figure 4.3A. Quantification of these effects are shown in Figure 4.3B. 
Deferoxamine is a ferrous iron chelator that is endocytosed (Doulias et al., 2003), 
and DFO significantly decreases the quenching of Phen Green, indicating there 
is a constitutive leak of Fe2+ from endolysosomes into the cytosol as shown in 
Figure 3C. Pretreatment with DFO prior to morphine treatment blocked the 
quenching of Phen Green, indicating a release of Fe2+ from endolysosomes into 
the cytosol by morphine as shown in Figure 4.3C by flow cytometry.  
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Endolysosome Iron is Taken up by Mitochondria 
 Rhodamine B 4-[(2,2'-bipyridin-4-yl)aminocarbonyl]benzyl ester (RDA) is a 
dye specific to Fe2+ and the mitochondria, and RDA fluorescence is 
stoichiometrically (3:1) quenched by Fe2+ ions (Rauen et al., 2007). U87MG cells 
were stained with RDA (100 nM), and the experiments were conducted from 
0 min to 30 min, times consistent with the rate of endolysosome de-acidification 
by morphine (Figure 4.1) and the release of Fe2+ from endolysosomes 
(Figures 4.2 and 4.3). Control cells stained with RDA were treated with PBS 
which did not yield significant changes to RDA fluorescence (Figure 4.4). 
Morphine quenched RDA fluorescence as shown in Figure 4.4.  
Morphine-induced Fe2+ Release from Endolysosomes Increases 
Mitochondrial ROS 
 Ferrous iron is a key reactant in the formation of the highly reactive 
hydroxyl radical and superoxide (Fenton, 1894). U87MG cells were stained with 
MitoSox, a mitochondrial measure of ROS. Morphine increased mitochondrial 
ROS, and DFO blocked morphine-induced mitochondrial ROS (Figure 4.5).  
Schematic Diagram of Overall Cellular Mechanisms 
 The schematic diagram of the proposed cellular mechanisms involved in 
these studies was illustrated in Figure 4.6. Morphine de-acidifies the pH of 
endolysosomes, releases iron into the cytosol, and iron is up-taken into 
mitochondria. The iron released from endolysosomes leads to increased levels of 
ROS in the cytosol and in mitochondria. DFO chelates endolysosome iron and 
inhibits ROS induced by morphine.
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Discussion 
 Although intracellular labile iron plays key roles in many cellular functions, 
excess iron has been implicated in promoting diseases and neurodegeneration 
(Padmanabhan et al., 2015, Rockfield et al., 2017). Moreover, a disrupted iron 
homeostasis has been established as a key factor in disease initiation and 
progression (Enns, 2003, Jellinger, 2009). Specifically, drugs of abuse have been 
observed to increase ROS and mitochondrial damage in the brain followed by a 
decrease in energy metabolism (Imam and Ali, 2000, Imam and Ali, 2001). 
Because iron is a key reactant in the formation of ROS and endolysosomes are 
major storage sites of ferrous iron, it was important to determine inter-organellar 
signaling between iron-rich endolysosomes and mitochondria (Fenton, 1894, Xu 
and Ren, 2015).  
 This study demonstrates that morphine, a drug of abuse, de-acidifies 
endolysosomes and releases Fe2+ into the cytosol. These findings are novel but 
are consistent with studies illustrating Ca2+ release with other de-acidifying 
agents (Christensen et al., 2002). Furthermore, this labile iron is translocated to 
the mitochondria resulting in increased ROS production and dysfunction. The 
morphine-induced formation of ROS is blocked with the iron chelator DFO, which 
emphasizes the significance of endolysosome iron.  
 In summary, these data confirm our hypothesis that endolysosome ferrous 
iron is an upstream event of morphine-induced mitochondrial ROS and 
dysfunction. DFO is a protectant from morphine-induced cytotoxicity, and 
emphasizes the importance of inter-organellar signaling of ferrous iron. Future 
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studies should include deferoxamine as a potential adjunctive strategy in the 
treatment of opioid use disorders. 
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Figure 4. 1.  Morphine de-acidified endolysosomes.  
(A) Morphine (10 µM) de-acidified endolysosome pH and 
naloxone (50 µM) inhibited morphine de-acidification.  
(B) Quantification of (A).  
(C) Morphine dose-dependently de-acidified endolysosome pH. 
Endolysosome de-acidification was measured using Lysosensor 
DND-160.  
(Vehicle for morphine and naloxone is PBS; n=30; * P < 0.05, ** 




Figure 4. 2.  Morphine decreased endolysosome iron.  
Morphine (10 µM) significantly decreased FeRhonox-1 
fluorescence intensity at 30 minutes and naloxone (50 µM) 
inhibited morphine’s effects. The change in fluorescence 
intensity was calculated as a percentage compared to the 
change in fluorescence intensity. 




Figure 4. 3.  Morphine increased cytosolic Fe2+:  
(A) Morphine (10 µM) quenched Phen-Green(the reciprocal of 
the Mean Fluorescent Intensity illustrates an increase in cytosolic 
iron), and naloxone (50 µM) inhibited morphine-induced iron 
release.  
(B) Quantification of (A).  
(C) DFO blocked morphine-induced quenching of Phen-Green, 
and DFO alone suppressed Phen-Green quenching, which 
indicates a constitutive leak of Fe2+.  
(n=5; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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Figure 4. 4.  Morphine increased mitochondrial Fe2+: Control cells stained 
with RDA and treated with PBS did not exhibit any significant 
changes in fluorescence intensity. Morphine (10 µM) quenched 
RDA fluorescence, and DFO inhibited morphine-induced RDA 
quenching. 




Figure 4. 5.  Chloroquine and bafilomycin A1 increased cytosolic ROS and 
mitochondrial ROS: Using MitoSox as a mitochondrial ROS 
measurement, morphine (10 µM) increased ROS, which was 
inhibited with DFO pretreatment.  




Figure 4. 6.  Schematic diagram of cellular mechanisms: Morphine-induced 
de-acidification of endolysosomes causes ferrous iron in 
endolysosomes to be released into the cytosol and into 
mitochondria thereby resulting in mitochondrial dysfunction. DFO 
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Abstract 
 HIV-associated neurocognitive disorder (HAND) affects 50% of people 
living with HIV-1 despite viral suppression achieved by antiretroviral therapies. 
Pathologically, brain tissue from HAND patients has shown morphological 
changes to intracellular organelles including endolysosomes and mitochondria. 
Moreover, people living with HIV-1 show elevated iron serum levels and iron 
chelators have been suggested as an adjuvant therapy to antiretroviral 
therapeutics. Mechanistically, soluble factors including the HIV-1 coat protein 
gp120 have been implicated in HAND pathogenesis. Here, we tested the 
hypothesis that HIV-1 gp120-induced de-acidification of endolysosomes leads to 
an efflux of iron from endolysosomes and a subsequent increase in levels of 
cytosolic and mitochondrial reactive oxygen species (ROS). We used U87MG 
glioblastoma cells and time-lapse confocal microscopy to measure gp120-
induced changes in endolysosome pH, endolysosome iron, cytosolic and 
mitochondrial iron, and ROS levels. HIV-1 gp120 de-acidified endolysosomes, 
reduced endolysosome iron levels, increased levels of cytosolic and 
mitochondrial iron, and increased levels of cytosolic and mitochondrial ROS. 
These effects were all attenuated significantly by the iron chelator deferoxamine 
that only enters cells via endocytosis. These results suggest that cellular and 
subcellular effects of HIV-1 gp120 can be downstream of its ability to de-acidify 
endolysosomes and increase the release of iron from endolysosomes. Thus, 
endolysosomes might represent an early and upstream target for therapeutic 
strategies against HAND. 
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Introduction 
 HIV-associated neurocognitive disorder (Bor et al.) affects about 50% of 
people living with HIV-1(PLWH) despite highly-effective viral suppression 
achieved using antiretroviral therapeutics (ART). Clinically, HAND is 
characterized by deficits in cognition, memory and motor function (Clifford and 
Ances, 2013); the severity of which varies from mild (asymptomatic) to severe 
(dementia) (Antinori et al., 2007). Pathologically, post mortem brain samples 
were found to exhibit decreased synaptodendritic arborization (Masliah et al., 
1997) (Everall et al., 1999), Alzheimer’s disease-like changes (Sacktor et al., 
2002), and morphological changes in subcellular organelles including 
endolysosomes (Gelman et al., 2005), endoplasmic reticulum (Lindl et al., 2007), 
and mitochondria (Avdoshina et al., 2016). Molecular contributors to HAND 
pathogenesis include HIV-1 proteins (Ogishi and Yotsuyanagi, 2018, Scutari et 
al., 2017), oxidative stress (Turchan et al., 2003), and the ART themselves 
(Heaton et al., 2011). However, the full spectrum of underlying mechanisms of 
HAND still remain unclear.  
 Implicated in the pathogenesis of HAND are a number of soluble factors 
including HIV-1 transactivator of transcription protein (Tat) and the glycoprotein 
120 (gp120) (Kovalevich and Langford, 2012). Tat and gp120 both are 
neurotoxic, decrease synaptodendritic arborization (Bruce-Keller et al., 2003, 
Toggas et al., 1996), and disrupt intracellular cation homeostasis (Haughey et al., 
2001, Nath et al., 1995). Furthermore, Tat and gp120 are capable of affecting the 
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structure and function of subcellular organelles including endolysosomes and 
mitochondria (Hui et al., 2012b, Bae et al., 2014, Avdoshina et al., 2016). 
 Endolysosomes are acidic organelles that participate in the regulation of 
many important physiological functions including plasma membrane repair 
(Jaiswal et al., 2002), cell homeostasis, energy metabolism (McKenna et al., 
2018), nutrient-dependent signal transduction (Zhang et al., 2016), and immune 
responses (Watts, 2012). Additionally, endolysosomes contain readily releasable 
stores of biologically-important cations including calcium and iron (Xiong and 
Zhu, 2016a). Efflux of calcium and iron from endolysosomes is induced when 
endolysosomes are de-acidified (Christensen et al., 2002, Fernández et al., 
2016a), and when endolysosome membrane integrity is disrupted (Hui et al., 
2012a, Hui et al., 2012b). Mitochondria too regulate a wide-variety of 
physiological functions, and when levels of calcium and iron are overloaded in 
mitochondria this results in increased levels of ROS (Brookes et al., 2004., 
Huang et al., 2017), toxic cellular responses, and cell death via apoptosis and 
ferroptosis (Dixon et al., 2012).  
 HIV-1 gp120 de-acidifies endolysosomes and increases levels of ROS 
(Viviani et al., 2001, Bae et al., 2014). The gp120-induced increases in cytosolic 
and mitochondrial ROS might result from endolysosome de-acidification-induced 
release of iron, increased iron accumulation in the cytoplasm and mitochondria, 
and formation of oxygen radicals mediated by the Fenton and Haber-Weiss 
reactions. Accordingly, we tested the hypothesis that gp120-induced de-
acidification of endolysosomes leads to decreased levels of iron in 
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endolysosomes and increased levels of iron in cytoplasm and mitochondria, and 
that chelation of endolysosome iron can block downstream gp120-induced 
increases in cytosolic and mitochondrial ROS.  
Materials and Methods 
Cell Cultures 
 Glioblastoma (U87MG) cells were cultured in 1x DMEM (Invitrogen) 
containing 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen). 
U87MG cells were grown in 35 mm2 dishes to confluence in a 5% CO2 incubator 
maintained at 37oC. Cells were not used past their tenth passage.  
Endolysosome pH Measurements 
 As previously described (Hui et al.) (Liu et al., 2000), endolysosome pH 
was measured using a ratiometric indicator-dye, LysoSensor Yellow/Blue DND-
160; a dual excitation dye that allows for pH measurements of acidic organelles 
that are independent of intracellular dye concentration. U87MG cells were loaded 
with 10 µM of DND-160 for 5 minutes at 37°C. Post-incubation, dye containing 
media was removed and fresh media was added to the cells just prior to them 
being taken for imaging. Light emitted at 520 nm in response to excitation for 
2 msec at 340 nm and 380 nm was measured every 10 seconds using a filter-
based imaging system (Zeiss, Germany). The ratios of light excited (340/380 nm) 
versus light emitted (520 nm) were converted to pH using a calibration curve 
established using 10 µM of the H+/Na+ ionophore monensin, and 20 µM of the 
H+/K+ ionophore nigericin; both were dissolved in a solution containing 20 mM  
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2-(N-morpholino) ethane sulfonic acid (MES), 110 mM KCl, and 20 mM NaCl, 
and the pH was adjusted to 3.0 to 7.0 with HCl/NaOH. 
Endolysosome Iron Measurements 
 FeRhoNox-1 (Goryo Chemical), which stains specifically for Fe2+, was 
added to cultured U87MG cells at a final concentration of 5 µM and cells were 
incubated at 37oC for 1 h after which they were washed twice with PBS. 
Following washing, fluorescence microscopy was used to visualize FeRhoNox-1 
fluorescence at absorption and fluorescence wavelengths of 537 nm and 569 
nm, respectively.  
Cytosolic Iron Measurements 
 U87MG cells were incubated with PhenGreen™ SK diacetate at a 
concentration of 10 µM for 30 minutes at 37oC. Cells were then washed three-
times with PBS and analyzed either with a ThermoFisher Attune flow cytometry 
(Alexa Fluor 488) or an Axiovert 200M (Zeiss) microscope-based system. 
Mitochondrial Iron Measurements 
 Mitochondrial iron levels were measured using rhodamine B-[2,2'-
bipyridine-4-yl)-aminocarbonyl]benzyl ester dye (RDA) (Squarix), a Fe2+-specific 
fluorescence dye that localizes within mitochondria (Lindl et al.). Cells were 
incubated with RDA at a concentration of 100 nM for 10 minutes at 37°C. Cells 
were washed once with PBS followed by the addition of fresh DMEM media and 
then were examined using confocal scanning microscopy (Zeiss LSM800); 
changes in RDA mean fluorescence intensity were measured 30 minutes after 
gp120 was added. The red fluorescence intensity of RDA was captured using 
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absorption and emission wavelengths of 562 nm and 598 nm, respectively and 
captured images were analyzed using ImageJ software. 
ROS Measurements in Cytosol and Mitochondria  
 Cytosolic ROS levels were measured using DCECF, 2,7-
dichlorodihydrofluoroscein diacetate (10 µM) and mitochondrial ROS was 
measured using MitoSox Red (5 µM). U87MG cells were incubated with DCECF 
or MitoSox Red for 30 minutes at 37ºC in serum-free media and then washed 
twice with PBS prior to being analyzed using confocal scanning microscopy 
(Zeiss LSM800). For MitoSox Red, images were captured using absorption and 
emission wavelengths of 510 and 580 nm, respectively. For DCECF, images 
were captured using absorption and emission wavelengths of 495 and 529 nm, 
respectively. All images were analyzed using ImageJ software.  
Cell Death Measurements 
 Cell death was measured using 20 ug/ml of propidium iodide (PI) staining 
(Sigma-Aldrich). U87MG cells were treated with gp120 (4 nM) in the absence or 
presence of DFO (100 µM) for 24-hours. Cells were then incubated with 
propidium iodide for 30 minutes and analyzed using an Attune NxT flow 
cytometer (ThermoFisher). PI-positive cells were identified using excitation and 
emission wavelengths of 493 and 636 nm, respectively. The percentage of PI-
positive versus total number of cells was determined using Attune NxT software. 
Cellular and Subcellular Morphology  
 Morphological features of U87MG cells and their subcellular organelles 
were determined by immunostaining for plasma membranes, nucleus, and 
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endolysosomes. Lysosomes were stained with an anti-LAMP1 antibody and an 
Alexa 488 anti-rabbit secondary antibody (Thermo Fisher. Plasma membranes 
were stained with an anti-beta1 sodium potassium ATPase antibody and an 
Alexa 594 anti-mouse antibody (Thermo Fischer). Nuclei were stained with DAPI 
(blue). Confocal scanning microscopy (Zeiss LSM800) was used to acquire 
images and when necessary Z-stack images were taken. Images were acquired 
and processed using Zen microscope imaging system software (Zeiss).  
Reagents 
 All reagents were purchased from Thermo Fisher Scientific unless noted 
otherwise. HIV-1 gp120 IIIb was purchased from ABL Inc and aliquots were 
prepared and stored at -80oC to prevent freeze-thaw problems.  
Statistics 
 All data were expressed as means and either S.D or S.E.M. Data 
analyses were completed using GraphPad Prism8 software. Statistical 
significance between two groups was determined using a Student's t test with a 
Welch’s correction that did not include an assumption that both groups had the 
same SD. One-way ANOVA with Tukey’s post-hoc tests were used to compare 
differences between multiple groups. p ≤ 0.05 was designated to be statistically 
significant. 
Results 
Effects of gp120 on Cell Viability  
 The main focus of the studies reported on here was to determine the 
effects of HIV-1 gp120 on intracellular levels of Fe2+ and ROS. Because HIV-1 
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gp120 has the capacity to decrease cell viability, it was first necessary to 
determine whether gp120-induced cell death occurred under the experimental 
conditions used for our endolysosome morphological and functional studies. 
Using propidium iodide (PI) staining as a measure of cell death, we determined 
first the extent to which 30 min incubations with 4 nM gp120 decreased cell 
viability of U87MG cells. No statistically significant changes in cell viability were 
observed (see Supplemental Figure 5.A). Next, we determined the extent to 
which 24 h incubations with 4 nM gp120 decreased cell viability of U87MG cells 
and again observed no statistically significant changes in cell viability with either 
gp120 or the iron chelator DFO alone or in combination. Thus, under the 
conditions used we were not studying the effects of cell death on levels of Fe2+ 
and ROS. 
Effects of gp120 on Endolysosome pH 
 Similar to our previously reported results on the effects of HIV-1 gp120 on 
endolysosome pH in primary cultures of rat hippocampal neurons (Bae et al., 
2014), we found that gp120 at a concentration of 4 nM significantly increased 
endolysosome pH in U87MG cells from control values of 5.28 + 0.05 pH units to 
values of 5.43 + 0.04 pH units for gp120-treated cells (Figure 2, n=15; p<0.001). 
On average gp120 treatment increased endolysosome pH by 0.15 pH units; this 
equals a 32% reduction in endolysosomes proton concentrations as calculated 
using the formula pH = -log[H+].  
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Effects of gp120 on U87MG Cell Morphology and  
Endolysosome Numbers and Volume 
 Endolysosome deacidification has been shown by others and us to cause 
changes in endolysosome morphology including their volume and numbers as 
well as the distribution of endolysosomes within multiple cell types. To determine 
the effects of gp120 on endolysosome morphology and number, we incubated 
U87MG cells with 4 nM gp120 for 30 minutes and then measured changes in 
LAMP1-positive endolysosomes. In Imaris reconstructed and confocal (inset) 
images, it is visually apparent that endolysosomes are fewer in number but 
greater in volume when exposed to gp120 or the v-ATPase inhibitor bafilomycin 
that is known to de-acidify endolysosomes (Figure 5.2A). Quantitatively, gp120 
significantly decreased significantly (p<0.0001) the number of endolysosomes 
(average number of LAMP1-positive vesicles per cell), but significantly 
(p<0.0001) increased the volume of LAMP1-positive endolysosomes 
(Figure 5.2B).  
gp120 Reduced the Levels of Iron within Endolysosomes 
 Next, we determined the degree to which gp120 released iron from 
endolysosomes. U87MG cells were incubated with 5 µM FeRhoNox-1 and 
fluorescence was measured 30-minutes after gp120 was added to the cells; 
gp120 significantly (p<0.001) decreased endolysosome iron levels by 49% 
(Figure 5.3).  
gp120 Increased Iron Levels in the Cytosol 
 To determine the effects of gp120 on the labile pool of cytosolic iron, we 
treated U87MG cells with PhenGreen SK (PG SK), which is a transition metal 
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indicator and a reported quenching probe for cytosolic iron (Petrat et al., 1999). 
First, we determined the extent to which gp120 increased levels of cytosolic iron 
and found that HIV-1 gp120 (4 nM) significantly (p<0.001) increased cytosolic 
iron levels (Figure 5.4). Next, we determined the extent to which the iron 
accumulating in the cytosol originated from endolysosomes. Using deferoxamine 
(DFO), an iron chelator that only enters cells by endocytosis (Cable and Lloyd, 
1999, Lloyd et al., 1991a), we found that DFO significantly (p<0.0001) blocked 
gp120-induced increases in cytosolic iron to levels that were significantly 
(p<0.05) less than those in control cells (Figure 4). For ease of illustration, our 
fluorescence data were transformed as 1/MFI to illustrate more readily the 
gp120-induced increases in cytosolic iron.  
gp120 Increased Mitochondrial Iron Levels 
 To determine the effects of gp120 on mitochondrial iron levels, we treated 
U87MG cells with rhodamine B-[2,2'-bipyridine-4-yl)-aminocarbonyl]benzyl ester 
dye (RDA; 100 nM) a dye whose fluorescence is quenched in the presence of 
mitochondrial ferrous iron (Rauen et al., 2007). For ease of illustration, our 
fluorescence data were transformed into 1/MFI to illustrate more readily the 
gp120-induced increases in mitochondrial iron. DFO by itself was found to cause 
a small but statistically significant (p<0.01) increase in levels of mitochondrial iron 
(Figure 5). gp120 (4 nM) significantly (p<0.0001) increased levels of 
mitochondrial iron (Figure 5.5). Pre-treatment of U87MG cells for 1hr with DFO 
significantly (p<0.001) blocked gp120-induced increases in mitochondrial iron 
level (Figure 5.5).  
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gp120 Increased Reactive Oxygen Species (ROS) in  
Cytosol and Mitochondria 
 An increase of free labile iron levels is a catalyst for the production of ROS 
through the Haber-Weiss and/or the Fenton reactions. Because we observed that 
gp120 increased levels of cytosolic and mitochondrial iron, we next explored the 
effects of gp120 on levels of ROS in the cytosol and mitochondria. DFO alone 
significantly (p<0.01) reduced ROS levels in cytosol (Figure 6A), but not in 
mitochondria (Figure 6B). gp120 (4 nM) significantly increased cytosolic 
(p<0.0001) and mitochondrial (p<0.001) ROS (Figures 6A and 6B). Pretreatment 
of cells with DFO for 1 h prior to the addition of gp120 decreased significantly 
levels of ROS in cytosol (p<0.001) and in mitochondria (p<0.01).  
Discussion 
 Over the past three decades, the development and use of effective 
antiretroviral therapeutics (ART) targeting HIV-1/AIDS has made this a 
manageable but chronic disease. Associated with HIV-1/AIDS in the ART-era is a 
high prevalence of neurological symptoms such has cognitive, motor, and 
behavioral problems that range in intensity from mild (asymptomatic) to severe 
(dementia) (13(Bhaskaran et al., 2008). Underlying the development of what has 
now been termed HIV-1 associated neurological disorders (HAND) are such 
pathological features as synaptodendritic damage, neuroinflammation, increased 
levels of oxidative stress, and damage to subcellular organelles (Everall et al., 
1999). Current investigative efforts focused on determining mechanisms causing 
HAND include the involvement of soluble factors such as HIV-1 proteins as well 
as ART treatments themselves (Ogishi and Yotsuyanagi, 2018) (Gelman et al., 
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2005) (Avdoshina et al., 2016) (Turchan et al., 2003) (Scutari et al., 2017). Here, 
we tested the hypothesis that HIV-1 gp120-induced de-acidification of 
endolysosomes leads to an efflux of iron from endolysosomes, an accumulation 
of iron in the cytosol and mitochondria, and a subsequent increase in levels of 
cytosolic and mitochondrial reactive oxygen species (ROS). The main findings of 
this work were that HIV-1 gp120 de-acidified endolysosomes, and that de-
acidification led to increased efflux of ferrous iron out of endolysosomes. Further, 
the efflux of iron from endolysosomes led to increased accumulation of iron in 
cytoplasm and mitochondria; the result of which was increased levels of cytosolic 
and mitochondrial ROS. Together, these results suggest that cellular and 
subcellular effects of HIV-1 gp120 can be downstream of its ability to de-acidify 
endolysosomes and increase the release of iron from endolysosomes. Thus, 
endolysosomes might represent an early and upstream target for therapeutic 
strategies against HAND. 
 HIV-1 gp120 has been shown to affect endolysosomes (Bae et al., 2014) 
and mitochondria (Avdoshina et al., 2016), however virtually nothing is known 
about the extent to which gp120-induced endolysosome dysfunction causes 
mitochondrial dysfunction. In the current era of cell biology, there is an increased 
emphasis on better understanding physical and functional cross-talk between 
subcellular organelles and how these interactions help maintain cellular 
homeostasis (Bravo-Sagua et al., 2014). Indeed, inter-organellar signaling has 
been implicated in the pathogenesis of multiple diseases including cancer and 
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neurodegenerative diseases (Hughes and Gottschling, 2012, Plotegher and 
Duchen, 2017).  
 Oxidative stress has been implicated in the pathogenesis of 
neurodegenerative diseases including HAND (Scutari et al., 2017, Turchan et al., 
2003), and the HIV-1 proteins gp120 and Tat have been shown by others and us 
to increase levels of ROS (Viviani et al., 2001). Implicated in the generation of 
ROS through the Fenton and Haber-Weiss reactions is iron and serum iron levels 
are elevated in PLWH (Nekhai et al., 2013). Ferric iron (Fe3+) is endocytosed 
when bound to transferrin where it is reduced to redox-active ferrous iron (Fe2+). 
Endolysosomes, which are acidic organelles, store ferrous iron and ferrous iron 
efflux is regulated by many factors including luminal pH and various cation 
channels (Fernández et al., 2016a). The iron released from endolysosomes can 
then accumulate in the cytoplasm and in mitochondria where it can generate 
ROS (Eaton and Qian, 2002).  
 Endolysosomes are dynamic organelles whose structure and function is 
closely regulated by changes in luminal pH. De-acidification of endolysosomes 
disrupts their trafficking, ability to degrade waste, and the maintenance of ion 
homeostasis (Christensen et al., 2002), (Fernández et al., 2016a). Previously, we 
reported that gp120 de-acidified neuronal endolysosomes (Bae et al., 2014). 
Here, we showed that gp120 de-acidified endolysosomes and increased their 
sizes while decreasing their numbers. The effects of gp120 are similar to the 
effects of HIV-1 Tat that we reported on previously; HIV-1 Tat disrupted 
endolysosome structure and increased endolysosome pH (Hui et al., 2012b). The 
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result of gp120-induced endolysosome de-acidification was increased release of 
ferrous iron from endolysosomes and the accumulation of ferrous iron in the 
cytosol and mitochondria. These effects were blocked completely by using the 
ferrous iron chelator deferoxamine that only enters cells by endocytosis (Doulias 
et al., 2003). Thus, it appears that gp120-induced ROS production is mediated 
upstream by endolysosome de-acidification and the release of their ferrous iron 
stores. Such a scenario where endolysosome iron might be transported into 
mitochondria was referred to as a “kiss and run” phenomenon (Hamdi et al., 
2016).  
 It is important to note that the effects observed in these studies were not 
due to gp120-induced cell death. Under the conditions used here, we did not find 
any significant cell death with incubations of gp120 for either 30 min or 24-h. 
Others have shown that gp120 induced U87MG cell proliferation (Valentín-
Guillama et al., 2018) by activation of glycolysis resulting in increased lipid and 
protein synthesis and cyto-protection by inducing GRP78 in astrocytomas (Lopez 
et al., 2017). However, it remains a possibility that over extended treatment 
intervals, gp120 by itself or in synergistic combination with other HIV-1 proteins 
could result in cell loss. Nevertheless, the effects of gp120 observed here were 
noted in the absence of measurable cell death. Thus, this study provides 
evidence that gp120 induces endolysosome de-acidification which leads to the 
efflux of iron from endolysosomes, the accumulation of iron in the cytosol and in 
mitochondria, and that the iron led to the increased production of cytosolic and 
mitochondrial ROS (Figure 5.7). This cross-talk between endolysosomes and 
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mitochondria might participate in the pathogenesis of HAND and endolysosomes 





Figure 5. 1.  HIV-1 gp120 treatment affected lysosome number and 
morphology.  
(A) Representative Imaris reconstructed and confocal (inset) 
images of control and treated U87 cells with the lysosomes 
stained green(α-LAMP1), plasma membrane stained red (α- 
beta1 sodium ATPase) and nucleus blue (DAPI).  
(B) U87 glioblastoma cells treated with gp120 (4nM) for 30 min 
showed a significant decrease in average number and a 
simultaneous increase in volume of LAMP1 vesicles compared 
to control. Bafilomycin A1 (0.2µM, 30 min) served as positive 
control.  





Figure 5. 2.  HIV-1 gp120 increased endolysosome pH in U87MG cells. 
Treatment of U87MG cells with HIV-1 gp120 (4 nM) for 30 min 
caused statistically significant (n=15; ***p<0.001) increases in 
endolysosome pH when compared to phosphate-buffered saline 




Figure 5. 3.  HIV-1 gp120 reduced levels of iron in endolysosomes. HIV-1 
gp120 (4 nM), but not phosphate buffered saline (PBS) vehicle 
significantly reduced the percentage mean fluorescence intensity 
(MFI) of FeRhoNox-1 staining for ferrous iron (Fe2+) in 
endolysosomes of U87MG cells.  
(n= 15; ***p<0.001). 
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Figure 5. 4.  HIV-1 gp120 increased cytosolic iron levels. HIV-1 gp120 
significantly (p<0.0001) decreased PhenGreen SK (PG SK) 
mean fluorescent intensity (MFI) in U87MG cells. Here, we 
transformed the data into 1/MFI to illustrate more clearly the 
gp120-induced increases in cytosolic iron (n=15; ****p<0.0001) 
because PhenGreen fluorescence quenches at high levels of 
iron. Deferoxamine (DFO, 100 µM) alone did not significantly 
affect PhenGreen MFI (n=15). Pretreatment of cells for 1 h with 
DFO (100 µM) followed by administration of gp120 (4 nM) 
significantly (***p<0.001) reduced the effects of gp120 on 
PhenGreen MFI (n=15).  
114 
 
Figure 5. 5.  HIV-1 gp120 increased mitochondrial iron levels. HIV-1 gp120 at 
4 nM significantly (****p<0.0001) increased mitochondrial iron 
levels (n=47), while DFO at 100 µM significantly (***p<0.001) 
reduced gp120-induced effects on mitochondrial iron levels 
(n=26). Deferoxamine (DFO, 100 µM) alone significantly 
(**p<0.01) increased levels of mitochondrial iron (n=15). 
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Figure 5. 6.  HIV-1 gp120-induced increases in cytosolic and mitochondrial 
reactive oxygen species were blocked by deferoxamine (DFO). 
(A) HIV-1 gp120 treatment significantly increased the mean 
fluorescence intensity (MFI) of DCECF,  
2,7-dichlorodihydrofluoroscein diacetate, a measure of cytosolic 
ROS (n=15; ****p<0.0001). Treatment of cells with DFO alone 
significantly reduced levels of mitochondrial ROS (n=15; 
**p<0.01). Treatment of cells with a combination of DFO and 
gp120 resulted in significantly (***p<0.001) reduced MFI 
compared to gp120 (n=15).  
(B) HIV-1 gp120 treatment significantly increased mitochondrial 
ROS. (n=15; ***p<0.001). A combination of DFO and gp120 
significantly (**p<0.01) reduced mitochondrial ROS. 
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Figure 5. 7.  Schematic representation of the effects of gp120 on 
endolysosomes and mitochondria. Internalized gp120 within 
endolysosomes increases endolysosome pH, which then triggers 
a release of ferrous iron from endolysosomes. The released 
ferrous iron can accumulate in the cytosol and in mitochondria 
where it can be oxidized via the Fenton reaction to produce 








Figure 5. A. Supplemental Figure: Effects of HIV-1 gp120 and DFO on cell 
death. Incubation of U87MG cells with HIV-1 gp120 (4 nM) for 30 
min did cause statistically significant decreases in propidium 
iodide mean fluorescence intensity.  
Incubation of U87MG cells for 24 h with HIV-1 gp120 (4 nM), 
DFO (100 µM), or gp120 in combination with DFO did cause 
statistically significant decreases in propidium iodide mean 
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 After ferric iron is released from enterocytes and macrophages into the 
bloodstream it binds to transferrin (Tf), which is an abundant plasma glycoprotein 
able to bind two atoms of iron with very high affinity (Aisen et al., 1978, Morgan, 
1981). Consequently, very little toxic iron is in the bloodstream (Anderson and 
Vulpe, 2009). Furthermore, the circulating Tf-Fe complex binds to the plasma 
membrane transferrin receptor 1 and the complex is endocytosed (Richardson 
and Ponka, 1997). Within endolysosomes ferric iron is reduced to ferrous iron by 
STEAP3, a metalloreductase (Ohgami et al., 2006). Therefore, it is well 
established that ferrous iron resides within endolysosomes (Starke and Farber, 
1985, Kurz et al., 2011). However, the concentration of ferrous iron within 
endolysosomes has yet to be determined. This study determined the level of 
ferrous iron concentration within endolysosomes as well as inter-organellar 
signaling of ferrous iron from endolysosomes to mitochondria. This present study 
was initiated under Dr. Geiger, who had returned from a conference where he 
discussed the effects of iron on mitochondria at a poster session. It was 
uncertain at the time where iron was coming from that might be leading to 
mitochondrial dysfunction. Thus, we began to look at the literature to further 
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investigate and study endolysosome iron as an upstream effect of mitochondrial 
dysfunction. 
 The present study, outlined in Chapter 2, was initiated by looking for a 
probe specific to Fe2+ and endolysosomes. About five years ago, the 
fluorescence ‘turn-on’ probe FeRhoNox-1 was found to have pronounced 
specificity for Fe2+ versus other biologically relevant metal ions (Mukaide, Hattori 
et al. 2014). It was also shown that FeRhoNox-1 labels Fe2+ stores in acidic Golgi 
organelles at least in some cells (Hirayama, Okuda et al. 2013). However, prior 
to our work, no reports have appeared determining whether FeRhoNox-1 labels 
Fe2+ in endolysosomes and whether FeRhoNox-1 can be used to quantitatively 
measure levels of Fe2+ in endolysosomes. Here, we found that FeRhoNox-1 was 
highly specific for Fe2+ versus other cations such as calcium, magnesium, copper 
and zinc. Further, FeRhoNox-1 positive stores were selectively localized in 
endolysosomes. FeRhonox-1 colocalized with LysoTracker with a high Pearson 
Correlation Coefficient of 0.84. FeRhonox-1 colocalized with EEA1-positive 
endolysosomes with a Pearson correlation coefficient of 0.86, and FeRhonox-1 
colocalized with LAMP1-positive late endosomes/lysosomes with a Pearson 
correlation coefficient of 0.56.  
 As a proof of principle for quantitative measurements of labile iron stores, 
endolysosome Fe2+ stores were increased with ferric ammonium citrate 
supplementation and were decreased with the iron chelator deferoxamine. 
Control levels of Fe2+ were 36.3 ± 13.6 µM in endolysosomes, and stores of Fe2+ 
in endolysosomes increased to 75 ± 15.7 µM when cells were incubated with 
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ferric ammonium citrate and decreased to 0.08 ± 0.05 µM when cells were 
incubated with the iron chelator deferoxamine. It is likely that FeRhoNox-1 will 
find extensive use for better understanding the physiological relevance and 
pathological significance of Fe2+ in living cells. Our findings demonstrate the 
utility of using FeRhoNox-1 to measure Fe2+ stores in endolysosomes and 
suggest that this probe will find important uses in better understanding cellular 
events downstream of released endolysosome Fe2+. 
 Endolysosomes are storage sites for readily-releasable ions including H+, 
Na+, K+, Cl-, Ca2+, Zn2+, Fe3+, and Fe2+ (Xu and Ren, 2015, Xiong and Zhu, 
2016b) as they integrate and digest materials compartmentalized by endocytosis, 
phagocytosis or autophagy. Further, studies have shown that drug-induced de-
acidification of the endolysosome lumen causes an efflux of cations such as Ca2+ 
from endolysosomes into the cytosol (Christensen et al., 2002, Fernández et al., 
2016b). With this knowledge, the study, outlined in Chapter 3, was to determine 
whether chloroquine and bafilomycin A1 would act like controls and release iron 
from endolysosomes as they both de-acidify endolysosome pH. It was 
determined that ferrous iron is released from endolysosomes upon treatment with 
chloroquine and bafilomycin A1. We determined that ferrous iron enters into the 
cytosol via two-pore channels and it is taken up by the mitochondria via 
mitochondrial permeability transition pores. The iron that enters the cytosol 
increases ROS levels and the iron that enters the mitochondria increases the 
ROS levels. These findings were further confirmed with the use of deferoxamine, 
which is an iron chelator that is cell impermeable and is taken up into cells by 
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endocytosis. DFO pretreatment chelated endolysosome iron and significantly 
blocked chloroquine- and bafilomycin A1-induced cytosolic and mitochondrial 
ROS levels.  
 Taken together, these findings demonstrate the importance of 
endolysosome ferrous iron as an upstream event of mitochondrial iron overload 
and dysfunction. Under pharmacological conditions such as chloroquine and 
bafilomycin A1, which de-acidify endolysosomes, ferrous iron accumulated in 
mitochondrial, increased mitochondrial ROS, and caused cell death. Since 
mitochondrial iron overload has been implicated in numerous diseases, these 
results open up new understandings of the role of endolysosome iron. 
 The study, as outlined in Chapter 4, was an extension of the previous 
Chapter 3 study. Morphine is a drug of abuse, and drugs of abuse have been 
associated with neurological diseases. More specifically, evidence shows that 
drugs of abuse increase free radicals and mitochondrial dysfunction such as 
decreased cellular energy production followed by toxicity (Imam and Ali, 2000, 
Imam and Ali, 2001, Stephans et al., 1998, Cunha-Oliveira et al., 2013, Xu et al., 
2011). Neuronal degeneration is associated with failed ATP production due to an 
increase in ROS and nitrogen species (Acikgoz et al., 1998, Binienda et al., 
1998), and studies have shown that neurotoxicity induced by drugs of abuse can 
be protected by antioxidants such as selenium and melatonin (Fosslien, 2001, 
Imam and Ali, 2000). However, the increase in mitochondrial ROS production 
induced by drugs of abuse remains uncertain. Our study demonstrated that 
morphine increased endolysosome pH, released ferrous iron into the cytosol, and 
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increased ferrous iron in mitochondria. Not surprisingly, morphine increased 
mitochondrial ROS levels. Furthermore, morphine effects were blocked by DFO. 
These results taken together shows that endolysosome iron is an upstream event 
of mitochondrial iron overload and dysfunction, and drugs of abuse, like 
morphine, affect mitochondrial function through inter-organellar signaling of 
ferrous iron.  
 The last study, Chapter 5, determined the effects of the HIV-1 protein 
gp120 on endolysosome iron and mitochondrial dysfunction. People living with 
HIV-1 show elevated iron serum levels and iron chelators have been suggested 
as an adjuvant therapy to antiretroviral therapeutics. Mechanistically, soluble 
factors including the HIV-1 coat protein gp120 have been implicated in HAND 
pathogenesis. Here, we determined that gp120 de-acidified endolysosomes, 
released iron into the cytosol, which is then taken up by the mitochondria. gp120 
lead to increased cytosolic ROS and mitochondrial ROS. DFO blocked gp120-
induced ROS and mitochondrial iron overload. These results suggest that cellular 
and subcellular effects of HIV-1 gp120 can be downstream of its ability to de-
acidify endolysosomes and increase the release of iron from endolysosomes, 
and that DFO might serve as adjunctive therapy.  
 The main mechanisms underlying these studies demonstrate some of the 
roles of ferrous iron within endolysosomes in inter-organellar signaling with 
mitochondria. Endolysosome ferrous iron plays an upstream role in mitochondrial 
iron overload, dysfunction, and cell death. These studies outline the key 
mechanisms of inter-organellar signaling and stress the significance that DFO 
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might serve as adjunctive therapy in protecting mitochondria from iron overload 
and dysfunction. With the probe of FeRhoNox-1 and the results within this 
dissertation, future studies should key on endolysosome ferrous iron and the 
roles this redox-active molecule has on normal cellular processes as well as 
cellular dysfunction and cell death. 
129 
REFERENCES 
ACIKGOZ, O., GONENC, S., KAYATEKIN, B. M., UYSAL, N., PEKCETIN, C., 
SEMIN, I. & GURE, A. 1998. Methamphetamine causes lipid peroxidation 
and an increase in superoxide dismutase activity in the rat striatum. Brain 
Res, 813, 200-2. 
 
AISEN, P., LEIBMAN, A. & ZWEIER, J. 1978. Stoichiometric and site 
characteristics of the binding of iron to human transferrin. Journal of 
Biological Chemistry, 253, 1930-1937. 
 
ANDERSEN, H. H., JOHNSEN, K. B. & MOOS, T. 2014. Iron deposits in the 
chronically inflamed central nervous system and contributes to 
neurodegeneration. Cell Mol Life Sci, 71, 1607-22. 
 
ANDERSON, G. J. & VULPE, C. D. 2009. Mammalian iron transport. Cellular and 
molecular life sciences : CMLS, 66, 3241-3261. 
 
ANDREYEV, A. Y., KUSHNAREVA, Y. E. & STARKOV, A. A. 2005. 
Mitochondrial metabolism of reactive oxygen species. Biochemistry 
(Mosc), 70, 200-14. 
 
ANTINORI, A., ARENDT, G., BECKER, J. T., BREW, B. J., BYRD, D. A., 
CHERNER, M., CLIFFORD, D. B., CINQUE, P., EPSTEIN, L. G., 
GOODKIN, K., GISSLEN, M., GRANT, I., HEATON, R. K., JOSEPH, J., 
MARDER, K., MARRA, C. M., MCARTHUR, J. C., NUNN, M., PRICE, R. 
W., PULLIAM, L., ROBERTSON, K. R., SACKTOR, N., VALCOUR, V. & 
WOJNA, V. E. 2007. Updated research nosology for HIV-associated 
neurocognitive disorders. Neurology, 69, 1789-99. 
 
AVDOSHINA, V., FIELDS, J. A., CASTELLANO, P., DEDONI, S., PALCHIK, G., 
TREJO, M., ADAME, A., ROCKENSTEIN, E., EUGENIN, E., MASLIAH, E. 
& MOCCHETTI, I. 2016. The HIV Protein gp120 Alters Mitochondrial 
Dynamics in Neurons. Neurotox Res, 29, 583-593. 
 
BAE, M., PATEL, N., XU, H., LEE, M., TOMINAGA-YAMANAKA, K., NATH, A., 
GEIGER, J., GOROSPE, M., MATTSON, M. P. & HAUGHEY, N. J. 2014. 
Activation of TRPML1 clears intraneuronal Abeta in preclinical models of 
HIV infection. J Neurosci, 34, 11485-503. 
130 
BALABAN, R. S., NEMOTO, S. & FINKEL, T. 2005. Mitochondria, oxidants, and 
aging. Cell, 120, 483-95. 
 
BALLAS, S. K., ZEIDAN, A. M., DUONG, V. H., DEVEAUX, M. & HEENEY, M. 
M. 2018. The effect of iron chelation therapy on overall survival in sickle 
cell disease and β-thalassemia: A systematic review. American Journal of 
Hematology, 93, 943-952. 
 
BERG, T. O., STRØMHAUG, P. E., LØVDAL, T., SEGLEN, P. O. & BERG, T. 
1994. Use of glycyl-<span class="sc">l</span>-phenylalanine 2-
naphthylamide, a lysosome-disrupting cathepsin C substrate, to 
distinguish between lysosomes and prelysosomal endocytic vacuoles. 
Biochemical Journal, 300, 229. 
 
BHASKARAN, K., HAMOUDA, O., SANNES, M., BOUFASSA, F., JOHNSON, A. 
M., LAMBERT, P. C., PORTER, K. & COLLABORATION, C. 2008. 
Changes in the risk of death after HIV seroconversion compared with 
mortality in the general population. JAMA, 300, 51-9. 
 
BINIENDA, Z., SIMMONS, C., HUSSAIN, S., SLIKKER, W., JR. & ALI, S. F. 
1998. Effect of acute exposure to 3-nitropropionic acid on activities of 
endogenous antioxidants in the rat brain. Neurosci Lett, 251, 173-6. 
 
BOCCACCIO, A., SCHOLZ-STARKE, J., HAMAMOTO, S., LARISCH, N., 
FESTA, M., GUTLA, P. V., COSTA, A., DIETRICH, P., UOZUMI, N. & 
CARPANETO, A. 2014. The phosphoinositide PI(3,5)P(2) mediates 
activation of mammalian but not plant TPC proteins: functional expression 
of endolysosomal channels in yeast and plant cells. Cell Mol Life Sci, 71, 
4275-83. 
 
BOR, D. H., WOOLHANDLER, S., NARDIN, R., BRUSCH, J. & HIMMELSTEIN, 
D. U. 2013. Infective Endocarditis in the U.S., 1998–2009: A Nationwide 
Study. PLoS One. 
 
BORDET, T., BERNA, P., ABITBOL, J.-L. & PRUSS, R. M. 2010. Olesoxime 
(TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. 
Pharmaceuticals (Basel, Switzerland), 3, 345-368. 
 
BOVERIS, A. & CADENAS, E. 1975. Mitochondrial production of superoxide 
anions and its relationship to the antimycin insensitive respiration. FEBS 
Lett, 54, 311-4. 
 
131 
BRAVO-SAGUA, R., TORREALBA, N., PAREDES, F., MORALES, P. E., 
PENNANEN, C., LOPEZ-CRISOSTO, C., TRONCOSO, R., CRIOLLO, A., 
CHIONG, M., HILL, J. A., SIMMEN, T., QUEST, A. F. & LAVANDERO, S. 
2014. Organelle communication: signaling crossroads between 
homeostasis and disease. Int J Biochem Cell Biol, 50, 55-9. 
 
BRENDA, C. 1898. "Ueber die Spermatogenese der Vertebraten und höherer 
Evertebraten. II. Theil: Die Histiogenese der Spermien. Arch. Anal. 
Physiol. 
 
BREWER, G. J. 2007. Iron and copper toxicity in diseases of aging, particularly 
atherosclerosis and Alzheimer's disease. Exp Biol Med (Maywood), 232, 
323-35. 
 
BREWER, G. J., TORRICELLI, J. R., EVEGE, E. K. & PRICE, P. J. 1993. 
Optimized survival of hippocampal neurons in B27-supplemented 
Neurobasal, a new serum-free medium combination. J Neurosci Res, 35, 
567-76. 
 
BROOKES, P. S., YOON, Y., ROBOTHAM, J. L., ANDERS, M. W. & SHEU, S. 
S. 2004. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J 
Physiol Cell Physiol, 287, C817-33. 
 
BRUCE-KELLER, A. J., CHAUHAN, A., DIMAYUGA, F. O., GEE, J., KELLER, J. 
N. & NATH, A. 2003. Synaptic transport of human immunodeficiency 
virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci, 
23, 8417-22. 
 
BYSTROM, L. M., GUZMAN, M. L. & RIVELLA, S. 2014. Iron and reactive 
oxygen species: friends or foes of cancer cells? Antioxidants & redox 
signaling, 20, 1917-1924. 
 
CABLE, H. & LLOYD, J. B. 1999. Cellular uptake and release of two contrasting 
iron chelators. J Pharm Pharmacol, 51, 131-4. 
 
CALCRAFT, P. J., RUAS, M., PAN, Z., CHENG, X., ARREDOUANI, A., HAO, X., 
TANG, J., RIETDORF, K., TEBOUL, L., CHUANG, K. T., LIN, P., XIAO, 
R., WANG, C., ZHU, Y., LIN, Y., WYATT, C. N., PARRINGTON, J., MA, 
J., EVANS, A. M., GALIONE, A. & ZHU, M. X. 2009. NAADP mobilizes 
calcium from acidic organelles through two-pore channels. Nature, 459, 
596-600. 
 
CANG, C., ARANDA, K., SEO, Y. J., GASNIER, B. & REN, D. 2015. TMEM175 




CAO, Q., ZHONG, X. Z., ZOU, Y., ZHANG, Z., TORO, L. & DONG, X. P. 2015. 
BK Channels Alleviate Lysosomal Storage Diseases by Providing Positive 
Feedback Regulation of Lysosomal Ca2+ Release. Dev Cell, 33, 427-41. 
 
CARROLL, C. B., ZEISSLER, M. L., CHADBORN, N., GIBSON, K., WILLIAMS, 
G., ZAJICEK, J. P., MORRISON, K. E. & HANEMANN, C. O. 2011. 
Changes in iron-regulatory gene expression occur in human cell culture 
models of Parkinson’s disease. Neurochemistry International, 59, 73-80. 
 
CHANCE, B., SIES, H. & BOVERIS, A. 1979. Hydroperoxide metabolism in 
mammalian organs. Physiol Rev, 59, 527-605. 
 
CHAVEZ-CROOKER, P., GARRIDO, N. & AHEARN, G. A. 2001. Copper 
transport by lobster hepatopancreatic epithelial cells separated by 
centrifugal elutriation: measurements with the fluorescent dye Phen 
Green. J Exp Biol, 204, 1433-44. 
 
CHEN, X., HUI, L., GEIGER, N. H., HAUGHEY, N. J. & GEIGER, J. D. 2013. 
Endolysosome involvement in HIV-1 transactivator protein-induced 
neuronal amyloid beta production. Neurobiol Aging, 34, 2370-8. 
 
CHENG, X., ZHANG, X., GAO, Q., ALI SAMIE, M., AZAR, M., TSANG, W. L., 
DONG, L., SAHOO, N., LI, X., ZHUO, Y., GARRITY, A. G., WANG, X., 
FERRER, M., DOWLING, J., XU, L., HAN, R. & XU, H. 2014. The 
intracellular Ca2+ channel MCOLN1 is required for sarcolemma repair to 
prevent muscular dystrophy. Nature Medicine, 20, 1187. 
 
CHRIST, W. J., ASANO, O., ROBIDOUX, A. L., PEREZ, M., WANG, Y., DUBUC, 
G. R., GAVIN, W. E., HAWKINS, L. D., MCGUINNESS, P. D., 
MULLARKEY, M. A. & ET AL. 1995. E5531, a pure endotoxin antagonist 
of high potency. Science, 268, 80-3. 
 
CHRISTENSEN, K. A., MYERS, J. T. & SWANSON, J. A. 2002. pH-dependent 
regulation of lysosomal calcium in macrophages. J Cell Sci, 115, 599-607. 
 
CLIFFORD, D. B. & ANCES, B. M. 2013. HIV-Associated Neurocognitive 
Disorder (HAND). Lancet Infect Dis, 13, 976-86. 
 
COLACURCIO, D. J. & NIXON, R. A. 2016. Disorders of lysosomal acidification-
The emerging role of v-ATPase in aging and neurodegenerative disease. 
Ageing Res Rev, 32, 75-88. 
 
CONNER, S. D. & SCHMID, S. L. 2003. Regulated portals of entry into the cell. 
Nature, 422, 37-44. 
 
133 
CUNHA-OLIVEIRA, T., SILVA, L., SILVA, A. M., MORENO, A. J., OLIVEIRA, C. 
R. & SANTOS, M. S. 2013. Mitochondrial complex I dysfunction induced 
by cocaine and cocaine plus morphine in brain and liver mitochondria. 
Toxicology Letters, 219, 298-306. 
 
DE DUVE, C. 2005. The lysosome turns fifty. Nature Cell Biology, 7, 847. 
 
DEFELICE, L. J. & GOSWAMI, T. 2007. Transporters as channels. Annu Rev 
Physiol, 69, 87-112. 
 
DI FIORE, P. P. & VON ZASTROW, M. 2014. Endocytosis, signaling, and 
beyond. Cold Spring Harb Perspect Biol, 6. 
 
DIXON, S. J., LEMBERG, K. M., LAMPRECHT, M. R., SKOUTA, R., ZAITSEV, 
E. M., GLEASON, C. E., PATEL, D. N., BAUER, A. J., CANTLEY, A. M., 
YANG, W. S., MORRISON, B., 3RD & STOCKWELL, B. R. 2012. 
Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149, 
1060-72. 
 
DONG, X. P., CHENG, X., MILLS, E., DELLING, M., WANG, F., KURZ, T. & XU, 
H. 2008. The type IV mucolipidosis-associated protein TRPML1 is an 
endolysosomal iron release channel. Nature, 455, 992-6. 
 
DONG, X. P., WANG, X. & XU, H. 2010. TRP channels of intracellular 
membranes. J Neurochem, 113, 313-28. 
 
DORN, G. W., 2ND, VEGA, R. B. & KELLY, D. P. 2015. Mitochondrial biogenesis 
and dynamics in the developing and diseased heart. Genes Dev, 29, 
1981-91. 
 
DOULIAS, P. T., CHRISTOFORIDIS, S., BRUNK, U. T. & GALARIS, D. 2003. 
Endosomal and lysosomal effects of desferrioxamine: protection of HeLa 
cells from hydrogen peroxide-induced DNA damage and induction of cell-
cycle arrest. Free Radic Biol Med, 35, 719-28. 
 
EATON, J. W. & QIAN, M. 2002. Molecular bases of cellular iron toxicity. Free 
Radic Biol Med, 32, 833-40. 
 
EICHELSDOERFER, J. L., EVANS, J. A., SLAUGENHAUPT, S. A. & 
CUAJUNGCO, M. P. 2010. Zinc dyshomeostasis is linked with the loss of 
mucolipidosis IV-associated TRPML1 ion channel. J Biol Chem, 285, 
34304-8. 
 
ENNS, G. M. 2003. The contribution of mitochondria to common disorders. 
Molecular Genetics and Metabolism, 80, 11-26. 
 
134 
ERNSTER, L. & SCHATZ, G. 1981. Mitochondria: a historical review. The 
Journal of cell biology, 91, 227s-255s. 
 
EVERALL, I. P., HEATON, R. K., MARCOTTE, T. D., ELLIS, R. J., 
MCCUTCHAN, J. A., ATKINSON, J. H., GRANT, I., MALLORY, M. & 
MASLIAH, E. 1999. Cortical synaptic density is reduced in mild to 
moderate human immunodeficiency virus neurocognitive disorder. HNRC 
Group. HIV Neurobehavioral Research Center. Brain Pathol, 9, 209-17. 
 
FENTON, H. J. H. 1894. LXXIII.—Oxidation of tartaric acid in presence of iron. 
Journal of the Chemical Society, Transactions, 65, 899-910. 
 
FERNÁNDEZ, B., FDEZ, E., GÓMEZ-SUAGA, P., GIL, F., MOLINA-VILLALBA, 
I., FERRER, I., PATEL, S., CHURCHILL, G. C. & HILFIKER, S. 2016a. 
Iron overload causes endolysosomal deficits modulated by NAADP-
regulated 2-pore channels and RAB7A. Autophagy. 
 
FERNÁNDEZ, B., FDEZ, E., GÓMEZ-SUAGA, P., GIL, F., MOLINA-VILLALBA, 
I., FERRER, I., PATEL, S., CHURCHILL, G. C. & HILFIKER, S. 2016b. 
Iron overload causes endolysosomal deficits modulated by NAADP-
regulated 2-pore channels and RAB7A. Autophagy, 12, 1487-1506. 
 
FESTA, L., GUTOSKEY, C. J., GRAZIANO, A., WATERHOUSE, B. D. & 
MEUCCI, O. 2015. Induction of Interleukin-1beta by Human 
Immunodeficiency Virus-1 Viral Proteins Leads to Increased Levels of 
Neuronal Ferritin Heavy Chain, Synaptic Injury, and Deficits in Flexible 
Attention. J Neurosci, 35, 10550-61. 
 
FORGAC, M. 2007. Vacuolar ATPases: rotary proton pumps in physiology and 
pathophysiology. Nat Rev Mol Cell Biol, 8, 917-29. 
 
FOSSLIEN, E. 2001. Mitochondrial medicine--molecular pathology of defective 
oxidative phosphorylation. Ann Clin Lab Sci, 31, 25-67. 
 
FUTTER, C. E., PEARSE, A., HEWLETT, L. J. & HOPKINS, C. R. 1996. 
Multivesicular endosomes containing internalized EGF-EGF receptor 
complexes mature and then fuse directly with lysosomes. The Journal of 
Cell Biology, 132, 1011. 
 
GELMAN, B. B., SOUKUP, V. M., HOLZER, C. E., 3RD, FABIAN, R. H., 
SCHUENKE, K. W., KEHERLY, M. J., RICHEY, F. J. & LAHART, C. J. 
2005. Potential role for white matter lysosome expansion in HIV-
associated dementia. J Acquir Immune Defic Syndr, 39, 422-5. 
 
GOLDSTEIN, J. L. & BROWN, M. S. 2015. A century of cholesterol and 
coronaries: from plaques to genes to statins. Cell, 161, 161-172.  
135 
GRIFFITHS, K. K. & LEVY, R. J. 2017. Evidence of Mitochondrial Dysfunction in 
Autism: Biochemical Links, Genetic-Based Associations, and Non-Energy-
Related Mechanisms. Oxid Med Cell Longev, 2017, 4314025. 
 
HAMDI, A., ROSHAN, T. M., KAHAWITA, T. M., MASON, A. B., SHEFTEL, A. D. 
& PONKA, P. 2016. Erythroid cell mitochondria receive endosomal iron by 
a "kiss-and-run" mechanism. Biochim Biophys Acta, 1863, 2859-2867. 
 
HAUGHEY, N. J., NATH, A., MATTSON, M. P., SLEVIN, J. T. & GEIGER, J. D. 
2001. HIV-1 Tat through phosphorylation of NMDA receptors potentiates 
glutamate excitotoxicity. J Neurochem, 78, 457-67. 
 
HEATON, R. K., FRANKLIN, D. R., ELLIS, R. J., MCCUTCHAN, J. A., 
LETENDRE, S. L., LEBLANC, S., CORKRAN, S. H., DUARTE, N. A., 
CLIFFORD, D. B., WOODS, S. P., COLLIER, A. C., MARRA, C. M., 
MORGELLO, S., MINDT, M. R., TAYLOR, M. J., MARCOTTE, T. D., 
ATKINSON, J. H., WOLFSON, T., GELMAN, B. B., MCARTHUR, J. C., 
SIMPSON, D. M., ABRAMSON, I., GAMST, A., FENNEMA-NOTESTINE, 
C., JERNIGAN, T. L., WONG, J., GRANT, I., GROUP, C. & GROUP, H. 
2011. HIV-associated neurocognitive disorders before and during the era 
of combination antiretroviral therapy: differences in rates, nature, and 
predictors. J Neurovirol, 17, 3-16. 
 
HIRAYAMA, T. 2018. Development of Chemical Tools for Imaging of Fe(II) Ions 
in Living Cells: A Review. Acta Histochem Cytochem, 51, 137-143. 
 
HIRAYAMA, T., OKUDA, K. & NAGASAWA, H. 2013. A highly selective turn-on 
fluorescent probe for iron(II) to visualize labile iron in living cells. 
 
HUANG, H., CHEN, J., LU, H., ZHOU, M., CHAI, Z. & HU, Y. 2017. Iron-induced 
generation of mitochondrial ROS depends on AMPK activity. Biometals, 
30, 623-628. 
 
HUGHES, A. L. & GOTTSCHLING, D. E. 2012. An early age increase in vacuolar 
pH limits mitochondrial function and lifespan in yeast. Nature, 492, 261-5. 
 
HUI, L., CHEN, X. & GEIGER, J. D. 2012a. Endolysosome involvement in LDL 
cholesterol-induced Alzheimer's disease-like pathology in primary cultured 
neurons. Life Sci, 91, 1159-68. 
 
HUI, L., CHEN, X., HAUGHEY, N. J. & GEIGER, J. D. 2012b. Role of 
endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN Neuro, 4, 243-52. 
 
136 
HUI, L., GEIGER, N. H., BLOOR-YOUNG, D., CHURCHILL, G. C., GEIGER, J. 
D. & CHEN, X. 2015. Release of calcium from endolysosomes increases 
calcium influx through N-type calcium channels: Evidence for acidic store-
operated calcium entry in neurons. Cell Calcium, 58, 617-27. 
 
IMAM, S. Z. & ALI, S. F. 2000. Selenium, an antioxidant, attenuates 
methamphetamine-induced dopaminergic toxicity and peroxynitrite 
generation. Brain Res, 855, 186-91. 
 
IMAM, S. Z. & ALI, S. F. 2001. Aging increases the susceptiblity to 
methamphetamine-induced dopaminergic neurotoxicity in rats: correlation 
with peroxynitrite production and hyperthermia. J Neurochem, 78, 952-9. 
 
IMERYUZ, N., TAHAN, V., SONSUZ, A., EREN, F., URAZ, S., YUKSEL, M., 
AKPULAT, S., OZCELIK, D., HAKLAR, G., CELIKEL, C., AVSAR, E. & 
TOZUN, N. 2007. Iron preloading aggravates nutritional steatohepatitis in 
rats by increasing apoptotic cell death. J Hepatol, 47, 851-9. 
 
ISHIBASHI, K., SUZUKI, M. & IMAI, M. 2000. Molecular cloning of a novel form 
(two-repeat) protein related to voltage-gated sodium and calcium 
channels. Biochem Biophys Res Commun, 270, 370-6. 
 
ISHIDA, Y., NAYAK, S., MINDELL, J. A. & GRABE, M. 2013. A model of 
lysosomal pH regulation. J Gen Physiol, 141, 705-20. 
 
JAESCHKE, H., GORES, G. J., CEDERBAUM, A. I., HINSON, J. A., 
PESSAYRE, D. & LEMASTERS, J. J. 2002. Mechanisms of 
hepatotoxicity. Toxicol Sci, 65, 166-76. 
 
JAISWAL, J. K., ANDREWS, N. W. & SIMON, S. M. 2002. Membrane proximal 
lysosomes are the major vesicles responsible for calcium-dependent 
exocytosis in nonsecretory cells. J Cell Biol, 159, 625-35. 
 
JELLINGER, K. A. 2009. Recent advances in our understanding of 
neurodegeneration. J Neural Transm (Vienna), 116, 1111-62. 
 
JENSEN, P. K. 1966. Antimycin-insensitive oxidation of succinate and reduced 
nicotinamide-adenine dinucleotide in electron-transport particles. I. pH 




JEZEGOU, A., LLINARES, E., ANNE, C., KIEFFER-JAQUINOD, S., O'REGAN, 
S., AUPETIT, J., CHABLI, A., SAGNE, C., DEBACKER, C., 
CHADEFAUX-VEKEMANS, B., JOURNET, A., ANDRE, B. & GASNIER, 
B. 2012. Heptahelical protein PQLC2 is a lysosomal cationic amino acid 
exporter underlying the action of cysteamine in cystinosis therapy. Proc 
Natl Acad Sci U S A, 109, E3434-43. 
 
JOHRI, A. & BEAL, M. F. 2012. Mitochondrial dysfunction in neurodegenerative 
diseases. J Pharmacol Exp Ther, 342, 619-30. 
 
KALINOWSKI, D. S. & RICHARDSON, D. R. 2007. Future of toxicology--iron 
chelators and differing modes of action and toxicity: the changing face of 
iron chelation therapy. Chem Res Toxicol, 20, 715-20. 
 
KASPER, D., PLANELLS-CASES, R., FUHRMANN, J. C., SCHEEL, O., ZEITZ, 
O., RUETHER, K., SCHMITT, A., POET, M., STEINFELD, R., 
SCHWEIZER, M., KORNAK, U. & JENTSCH, T. J. 2005. Loss of the 
chloride channel ClC-7 leads to lysosomal storage disease and 
neurodegeneration. Embo j, 24, 1079-91. 
 
KAUR, J. & DEBNATH, J. 2015. Autophagy at the crossroads of catabolism and 
anabolism. Nat Rev Mol Cell Biol, 16, 461-72. 
 
KEBERLE, H. 1964. THE BIOCHEMISTRY OF DESFERRIOXAMINE AND ITS 
RELATION TO IRON METABOLISM. Ann N Y Acad Sci, 119, 758-68. 
 
KEHRER, J. P. 2000. The Haber-Weiss reaction and mechanisms of toxicity. 
Toxicology, 149, 43-50. 
 
KISELYOV, K., COLLETTI, G. A., TERWILLIGER, A., KETCHUM, K., LYONS, C. 
W., QUINN, J. & MUALLEM, S. 2011. TRPML: transporters of metals in 
lysosomes essential for cell survival? Cell Calcium, 50, 288-94. 
 
KOPPENOL, W. H. 2001. The Haber-Weiss cycle – 70 years later. Redox 
Report, 6, 229-234. 
 
KOVALEVICH, J. & LANGFORD, D. 2012. Neuronal toxicity in HIV CNS disease. 
Future Virol, 7, 687-698. 
 
KTISTAKIS, N. T. & TOOZE, S. A. 2016. Digesting the Expanding Mechanisms 
of Autophagy. Trends Cell Biol, 26, 624-635. 
 
KUMFU, S., CHATTIPAKORN, S., FUCHAROEN, S. & CHATTIPAKORN, N. 
2012. Mitochondrial calcium uniporter blocker prevents cardiac 
mitochondrial dysfunction induced by iron overload in thalassemic mice. 
Biometals, 25, 1167-75.  
138 
KURZ, T., EATON, J. W. & BRUNK, U. T. 2011. The role of lysosomes in iron 
metabolism and recycling. Int J Biochem Cell Biol, 43, 1686-97. 
 
LAFOURCADE, C., SOBO, K., KIEFFER-JAQUINOD, S., GARIN, J. & VAN DER 
GOOT, F. G. 2008. Regulation of the V-ATPase along the Endocytic 
Pathway Occurs through Reversible Subunit Association and Membrane 
Localization. PLOS ONE, 3, e2758. 
 
LANGE, P. F., WARTOSCH, L., JENTSCH, T. J. & FUHRMANN, J. C. 2006. 
ClC-7 requires Ostm1 as a beta-subunit to support bone resorption and 
lysosomal function. Nature, 440, 220-3. 
 
LELLOUCH, A. 1993. [Metchnikoff (1845-1916) and aging]. Hist Sci Med, 27, 13-
22. 
 
LESNEFSKY, E. J., MOGHADDAS, S., TANDLER, B., KERNER, J. & HOPPEL, 
C. L. 2001. Mitochondrial Dysfunction in Cardiac Disease: Ischemia–
Reperfusion, Aging, and Heart Failure. Journal of Molecular and Cellular 
Cardiology, 33, 1065-1089. 
 
LINDL, K. A., AKAY, C., WANG, Y., WHITE, M. G. & JORDAN-SCIUTTO, K. L. 
2007. Expression of the endoplasmic reticulum stress response marker, 
BiP, in the central nervous system of HIV-positive individuals. Neuropathol 
Appl Neurobiol, 33, 658-69. 
 
LIU, B., DU, H., RUTKOWSKI, R., GARTNER, A. & WANG, X. 2012. LAAT-1 is 
the lysosomal lysine/arginine transporter that maintains amino acid 
homeostasis. Science, 337, 351-4. 
 
LIU, Y., JONES, M., HINGTGEN, C. M., BU, G., LARIBEE, N., TANZI, R. E., 
MOIR, R. D., NATH, A. & HE, J. J. 2000. Uptake of HIV-1 tat protein 
mediated by low-density lipoprotein receptor-related protein disrupts the 
neuronal metabolic balance of the receptor ligands. Nat Med, 6, 1380-7. 
 
LIU, Z. D. & HIDER, R. C. 2002. Design of clinically useful iron(III)-selective 
chelators. Med Res Rev, 22, 26-64. 
 
LLOYD, J. B., CABLE, H. & RICE-EVANS, C. 1991a. Evidence that 
desferrioxamine cannot enter cells by passive diffusion. Biochem 
Pharmacol, 41, 1361-3. 
 
LLOYD, J. B., CABLE, H. & RICE-EVANS, C. 1991b. Evidence that 
desferrioxamine cannot enter cells by passive diffusion. Biochemical 
Pharmacology, 41, 1361-1363. 
 
139 
LLOYD-EVANS, E., MORGAN, A. J., HE, X., SMITH, D. A., ELLIOT-SMITH, E., 
SILLENCE, D. J., CHURCHILL, G. C., SCHUCHMAN, E. H., GALIONE, A. 
& PLATT, F. M. 2008. Niemann-Pick disease type C1 is a sphingosine 
storage disease that causes deregulation of lysosomal calcium. Nat Med, 
14, 1247-55. 
 
LOPEZ, S. N., RODRIGUEZ-VALENTIN, M., RIVERA, M., RODRIGUEZ, M., 
BABU, M., CUBANO, L. A., XIONG, H., WANG, G., KUCHERYAVYKH, L. 
& BOUKLI, N. M. 2017. HIV-1 Gp120 clade B/C induces a GRP78 driven 
cytoprotective mechanism in astrocytoma. Oncotarget, 8, 68415-68438. 
 
LOSCHEN, G., AZZI, A., RICHTER, C. & FLOHE, L. 1974. Superoxide radicals 
as precursors of mitochondrial hydrogen peroxide. FEBS Lett, 42, 68-72. 
 
LUZIO, J. P., BRIGHT, N. A. & PRYOR, P. R. 2007. The role of calcium and 
other ions in sorting and delivery in the late endocytic pathway. Biochem 
Soc Trans, 35, 1088-91. 
 
LUZIO, J. P., ROUS, B. A., BRIGHT, N. A., PRYOR, P. R., MULLOCK, B. M. & 
PIPER, R. C. 2000. Lysosome-endosome fusion and lysosome 
biogenesis. J Cell Sci, 113 ( Pt 9), 1515-24. 
 
MACKENZIE, B. & ERICKSON, J. D. 2004. Sodium-coupled neutral amino acid 
(System N/A) transporters of the SLC38 gene family. Pflugers Arch, 447, 
784-95. 
 
MASLIAH, E., HEATON, R. K., MARCOTTE, T. D., ELLIS, R. J., WILEY, C. A., 
MALLORY, M., ACHIM, C. L., MCCUTCHAN, J. A., NELSON, J. A., 
ATKINSON, J. H. & GRANT, I. 1997. Dendritic injury is a pathological 
substrate for human immunodeficiency virus-related cognitive disorders. 
HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol, 
42, 963-72. 
 
MCBRIDE, H. M., NEUSPIEL, M. & WASIAK, S. 2006. Mitochondria: more than 
just a powerhouse. Curr Biol, 16, R551-60. 
 
MCKENNA, M. C., SCHUCK, P. F. & FERREIRA, G. C. 2018. Fundamentals of 
CNS energy metabolism and alterations in lysosomal storage diseases. J 
Neurochem. 
 
MEDINA, D. L., FRALDI, A., BOUCHE, V., ANNUNZIATA, F., MANSUETO, G., 
SPAMPANATO, C., PURI, C., PIGNATA, A., MARTINA, J. A., 
SARDIELLO, M., PALMIERI, M., POLISHCHUK, R., PUERTOLLANO, R. 
& BALLABIO, A. 2011. Transcriptional activation of lysosomal exocytosis 
promotes cellular clearance. Dev Cell, 21, 421-30. 
 
140 
MELLMAN, I. 1996. ENDOCYTOSIS AND MOLECULAR SORTING. Annual 
Review of Cell and Developmental Biology, 12, 575-625. 
 
MENA, N. P., URRUTIA, P. J., LOURIDO, F., CARRASCO, C. M. & NÚÑEZ, M. 
T. 2015. Mitochondrial iron homeostasis and its dysfunctions in 
neurodegenerative disorders. Mitochondrion, 21, 92-105. 
 
MILLS, E., DONG, X. P., WANG, F. & XU, H. 2010. Mechanisms of brain iron 
transport: insight into neurodegeneration and CNS disorders. Future Med 
Chem, 2, 51-64. 
 
MINDELL, J. A. 2012a. Lysosomal acidification mechanisms. Annu Rev Physiol, 
74, 69-86. 
 
MINDELL, J. A. 2012b. Lysosomal Acidification Mechanisms. Annual Review of 
Physiology, 74, 69-86. 
 
MIZUSHIMA, N. & KOMATSU, M. 2011. Autophagy: renovation of cells and 
tissues. Cell, 147, 728-41. 
 
MOBARRA, N., SHANAKI, M., EHTERAM, H., NASIRI, H., SAHMANI, M., 
SAEIDI, M., GOUDARZI, M., POURKARIM, H. & AZAD, M. 2016. A 
Review on Iron Chelators in Treatment of Iron Overload Syndromes. 
International journal of hematology-oncology and stem cell research, 10, 
239-247. 
 
MORGAN, A. J., PLATT, F. M., LLOYD-EVANS, E. & GALIONE, A. 2011. 
Molecular mechanisms of endolysosomal Ca2+ signalling in health and 
disease. Biochem J, 439, 349-74. 
 
MORGAN, E. H. 1981. Transferrin, biochemistry, physiology and clinical 
significance. Molecular Aspects of Medicine, 4, 1-123. 
 
MOTULSKY, A. G. 1986. The 1985 Nobel Prize in physiology or medicine. 
Science, 231, 126-9. 
 
MUKAIDE, T., HATTORI, Y., MISAWA, N., FUNAHASHI, S., JIANG, L., 
HIRAYAMA, T., NAGASAWA, H. & TOYOKUNI, S. 2014. Histological 
detection of catalytic ferrous iron with the selective turn-on fluorescent 
probe RhoNox-1 in a Fenton reaction-based rat renal carcinogenesis 
model. Free Radic Res, 48, 990-5. 
 
MULLER, F. 2000. The nature and mechanism of superoxide production by the 




MURPHY, M. P. 2009. How mitochondria produce reactive oxygen species. The 
Biochemical journal, 417, 1-13. 
 
NATH, A., PADUA, R. A. & GEIGER, J. D. 1995. HIV-1 coat protein gp120-
induced increases in levels of intrasynaptosomal calcium. Brain Res, 678, 
200-6. 
 
NEKHAI, S., KUMARI, N. & DHAWAN, S. 2013. Role of cellular iron and oxygen 
in the regulation of HIV-1 infection. Future Virol, 8, 301-11. 
 
NIWA, M., HIRAYAMA, T., OKUDA, K. & NAGASAWA, H. 2014. A new class of 
high-contrast Fe(II) selective fluorescent probes based on spirocyclized 
scaffolds for visualization of intracellular labile iron delivered by transferrin. 
Org Biomol Chem, 12, 6590-7. 
 
OGISHI, M. & YOTSUYANAGI, H. 2018. Prediction of HIV-associated 
neurocognitive disorder (HAND) from three genetic features of envelope 
gp120 glycoprotein. Retrovirology, 15, 12. 
 
OHGAMI, R. S., CAMPAGNA, D. R., MCDONALD, A. & FLEMING, M. D. 2006. 
The Steap proteins are metalloreductases. Blood, 108, 1388. 
 
PADMANABHAN, H., BROOKES, M. J. & IQBAL, T. 2015. Iron and colorectal 
cancer: evidence from in vitro and animal studies. Nutr Rev, 73, 308-17. 
 
PELIZZONI, I., MACCO, R., MORINI, M. F., ZACCHETTI, D., GROHOVAZ, F. & 
CODAZZI, F. 2011. Iron handling in hippocampal neurons: activity-
dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell, 
10, 172-83. 
 
PERERA, R. M. & ZONCU, R. 2016. The Lysosome as a Regulatory Hub. Annu 
Rev Cell Dev Biol, 32, 223-253. 
 
PETERSEN, D. R. 2005. Alcohol, iron-associated oxidative stress, and cancer. 
Alcohol, 35, 243-9. 
 
PETRAT, F., DE GROOT, H., SUSTMANN, R. & RAUEN, U. 2002. The 
chelatable iron pool in living cells: a methodically defined quantity. Biol 
Chem, 383, 489-502. 
 
PETRAT, F., RAUEN, U. & DE GROOT, H. 1999. Determination of the 
chelatable iron pool of isolated rat hepatocytes by digital fluorescence 




PITCHER, J., ABT, A., MYERS, J., HAN, R., SNYDER, M., GRAZIANO, A., 
FESTA, L., KUTZLER, M., GARCIA, F., GAO, W. J., FISCHER-SMITH, T., 
RAPPAPORT, J. & MEUCCI, O. 2014. Neuronal ferritin heavy chain and 
drug abuse affect HIV-associated cognitive dysfunction. J Clin Invest, 124, 
656-69. 
 
PLOTEGHER, N. & DUCHEN, M. R. 2017. Mitochondrial Dysfunction and 
Neurodegeneration in Lysosomal Storage Disorders. Trends Mol Med, 23, 
116-134. 
 
PU, J., GUARDIA, C. M., KEREN-KAPLAN, T. & BONIFACINO, J. S. 2016. 
Mechanisms and functions of lysosome positioning. Journal of cell 
science, 129, 4329-4339. 
 
RAUEN, U., SPRINGER, A., WEISHEIT, D., PETRAT, F., KORTH, H. G., DE 
GROOT, H. & SUSTMANN, R. 2007. Assessment of chelatable 
mitochondrial iron by using mitochondrion-selective fluorescent iron 
indicators with different iron-binding affinities. Chembiochem, 8, 341-52. 
 
RICHARDSON, D. R., KALINOWSKI, D. S., LAU, S., JANSSON, P. J. & 
LOVEJOY, D. B. 2009. Cancer cell iron metabolism and the development 
of potent iron chelators as anti-tumour agents. Biochim Biophys Acta, 
1790, 702-17. 
 
RICHARDSON, D. R. & PONKA, P. 1997. The molecular mechanisms of the 
metabolism and transport of iron in normal and neoplastic cells. 
Biochimica et Biophysica Acta - Reviews on Biomembranes, 1331, 1-40. 
 
RIGOBELLO, M. P., SCUTARI, G., BOSCOLO, R. & BINDOLI, A. 2002. 
Induction of mitochondrial permeability transition by auranofin, a gold(I)-
phosphine derivative. British journal of pharmacology, 136, 1162-1168. 
 
RIVERO-RIOS, P., FERNANDEZ, B., MADERO-PEREZ, J., LOZANO, M. R. & 
HILFIKER, S. 2016. Two-Pore Channels and Parkinson's Disease: 
Where's the Link? Messenger (Los Angel), 5, 67-75. 
 
ROCKFIELD, S., RAFFEL, J., MEHTA, R., REHMAN, N. & NANJUNDAN, M. 
2017. Iron overload and altered iron metabolism in ovarian cancer. Biol 
Chem, 398, 995-1007. 
 
RONG, Y., LIU, M., MA, L., DU, W., ZHANG, H., TIAN, Y., CAO, Z., LI, Y., REN, 
H., ZHANG, C., LI, L., CHEN, S., XI, J. & YU, L. 2012. Clathrin and 
phosphatidylinositol-4,5-bisphosphate regulate autophagic lysosome 
reformation. Nat Cell Biol, 14, 924-34. 
 
143 
ROUAULT, T. A. & TONG, W.-H. 2005. Iron–sulphur cluster biogenesis and 
mitochondrial iron homeostasis. Nature Reviews Molecular Cell Biology, 6, 
345-351. 
 
SACKTOR, N., MCDERMOTT, M. P., MARDER, K., SCHIFITTO, G., SELNES, 
O. A., MCARTHUR, J. C., STERN, Y., ALBERT, S., PALUMBO, D., 
KIEBURTZ, K., DE MARCAIDA, J. A., COHEN, B. & EPSTEIN, L. 2002. 
HIV-associated cognitive impairment before and after the advent of 
combination therapy. J Neurovirol, 8, 136-42. 
 
SAGNE, C., AGULHON, C., RAVASSARD, P., DARMON, M., HAMON, M., EL 
MESTIKAWY, S., GASNIER, B. & GIROS, B. 2001. Identification and 
characterization of a lysosomal transporter for small neutral amino acids. 
Proc Natl Acad Sci U S A, 98, 7206-11. 
 
SAITO, M., HANSON, P. I. & SCHLESINGER, P. 2007. Luminal chloride-
dependent activation of endosome calcium channels: patch clamp study of 
enlarged endosomes. J Biol Chem, 282, 27327-33. 
 
SCHWABE, R. F. & BRENNER, D. A. 2006. Mechanisms of Liver Injury. I. TNF-
alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J 
Physiol Gastrointest Liver Physiol, 290, G583-9. 
 
SCUTARI, R., ALTERI, C., PERNO, C. F., SVICHER, V. & AQUARO, S. 2017. 
The Role of HIV Infection in Neurologic Injury. Brain Sci, 7. 
 
SENGUPTA, R., BURBASSI, S., SHIMIZU, S., CAPPELLO, S., VALLEE, R. B., 
RUBIN, J. B. & MEUCCI, O. 2009. Morphine increases brain levels of 
ferritin heavy chain leading to inhibition of CXCR4-mediated survival 
signaling in neurons. J Neurosci, 29, 2534-44. 
 
SETTEMBRE, C. & BALLABIO, A. 2013. New targets for old diseases: lessons 
from mucolipidosis type II. EMBO Mol Med, 5, 1801-3. 
 
SETTEMBRE, C., FRALDI, A., MEDINA, D. L. & BALLABIO, A. 2013. Signals 
from the lysosome: a control centre for cellular clearance and energy 
metabolism. Nat Rev Mol Cell Biol, 14, 283-96. 
 
SHIMIZU, S., ABT, A. & MEUCCI, O. 2011. Bilaminar co-culture of primary rat 
cortical neurons and glia. J Vis Exp. 
 
SIEKEVITZ, P. 1957. Powerhouse of the Cell. Scientific American, 197, 131-144. 
 
144 
SRIPETCHWANDEE, J., KENKNIGHT, S. B., SANIT, J., CHATTIPAKORN, S. & 
CHATTIPAKORN, N. 2014. Blockade of mitochondrial calcium uniporter 
prevents cardiac mitochondrial dysfunction caused by iron overload. Acta 
Physiol (Oxf), 210, 330-41. 
 
STARKE, P. E. & FARBER, J. L. 1985. Ferric iron and superoxide ions are 
required for the killing of cultured hepatocytes by hydrogen peroxide. 
Evidence for the participation of hydroxyl radicals formed by an iron-
catalyzed Haber-Weiss reaction. J Biol Chem, 260, 10099-104. 
 
STAUBER, T. & JENTSCH, T. J. 2013. Chloride in vesicular trafficking and 
function. Annu Rev Physiol, 75, 453-77. 
 
STEHLING, O., MASCARENHAS, J., VASHISHT, AJAY A., SHEFTEL, ALEX D., 
NIGGEMEYER, B., RÖSSER, R., PIERIK, ANTONIO J., 
WOHLSCHLEGEL, JAMES A. & LILL, R. 2013. Human CIA2A-FAM96A 
and CIA2B-FAM96B Integrate Iron Homeostasis and Maturation of 
Different Subsets of Cytosolic-Nuclear Iron-Sulfur Proteins. Cell 
Metabolism, 18, 187-198. 
 
STEINBERG, B. E., HUYNH, K. K., BRODOVITCH, A., JABS, S., STAUBER, T., 
JENTSCH, T. J. & GRINSTEIN, S. 2010. A cation counterflux supports 
lysosomal acidification. J Cell Biol, 189, 1171-86. 
 
STEINMAN, R. M., MELLMAN, I. S., MULLER, W. A. & COHN, Z. A. 1983. 
Endocytosis and the recycling of plasma membrane. J Cell Biol, 96, 1-27. 
 
STEPHANS, S. E., WHITTINGHAM, T. S., DOUGLAS, A. J., LUST, W. D. & 
YAMAMOTO, B. K. 1998. Substrates of energy metabolism attenuate 
methamphetamine-induced neurotoxicity in striatum. J Neurochem, 71, 
613-21. 
 
STOORVOGEL, W., STROUS, G. J., GEUZE, H. J., OORSCHOT, V. & 
SCHWARTZT, A. L. 1991. Late endosomes derive from early endosomes 
by maturation. Cell, 65, 417-427. 
 
SWANSON, C. A. 2003. Iron intake and regulation: implications for iron 
deficiency and iron overload. Alcohol, 30, 99-102. 
 
TAPIERO, H. & TEW, K. D. 2003. Trace elements in human physiology and 
pathology: zinc and metallothioneins. Biomed Pharmacother, 57, 399-411. 
 
TAPPER, H. & SUNDLER, R. 1995. Bafilomycin A1 inhibits lysosomal, 
phagosomal, and plasma membrane H(+)-ATPase and induces lysosomal 
enzyme secretion in macrophages. J Cell Physiol, 163, 137-44. 
 
145 
THOMAS, F., SERRATRICE, G., BEGUIN, C., AMAN, E. S., PIERRE, J. L., 
FONTECAVE, M. & LAULHERE, J. P. 1999. Calcein as a fluorescent 
probe for ferric iron. Application to iron nutrition in plant cells. J Biol Chem, 
274, 13375-83. 
 
TOGGAS, S. M., MASLIAH, E. & MUCKE, L. 1996. Prevention of HIV-1 gp120-
induced neuronal damage in the central nervous system of transgenic 
mice by the NMDA receptor antagonist memantine. Brain Res, 706, 303-7. 
 
TURCHAN, J., POCERNICH, C. B., GAIROLA, C., CHAUHAN, A., SCHIFITTO, 
G., BUTTERFIELD, D. A., BUCH, S., NARAYAN, O., SINAI, A., GEIGER, 
J., BERGER, J. R., ELFORD, H. & NATH, A. 2003. Oxidative stress in HIV 
demented patients and protection ex vivo with novel antioxidants. 
Neurology, 60, 307-14. 
 
UCHIYAMA, A., KIM, J. S., KON, K., JAESCHKE, H., IKEJIMA, K., WATANABE, 
S. & LEMASTERS, J. J. 2008. Translocation of iron from lysosomes into 
mitochondria is a key event during oxidative stress-induced hepatocellular 
injury. Hepatology, 48, 1644-54. 
 
URRUTIA, P. J., MENA, N. P. & NUNEZ, M. T. 2014. The interplay between iron 
accumulation, mitochondrial dysfunction, and inflammation during the 
execution step of neurodegenerative disorders. Front Pharmacol, 5, 38. 
 
VALENTÍN-GUILLAMA, G., LÓPEZ, S., KUCHERYAVYKH, Y. V., CHORNA, N. 
E., PÉREZ, J., ORTIZ-RIVERA, J., INYUSHIN, M., MAKAROV, V., 
VALENTÍN-ACEVEDO, A., QUINONES-HINOJOSA, A., BOUKLI, N. & 
KUCHERYAVYKH, L. Y. 2018. HIV-1 Envelope Protein gp120 Promotes 
Proliferation and the Activation of Glycolysis in Glioma Cell. Cancers 
(Basel). 
 
VIDELA, L. A., FERNANDEZ, V., TAPIA, G. & VARELA, P. 2003. Oxidative 
stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells. 
Biometals, 16, 103-11. 
 
VIVIANI, B., CORSINI, E., BINAGLIA, M., GALLI, C. L. & MARINOVICH, M. 
2001. Reactive oxygen species generated by glia are responsible for 
neuron death induced by human immunodeficiency virus-glycoprotein 120 
in vitro. Neuroscience, 107, 51-8. 
 
WANG, S., TSUN, Z. Y., WOLFSON, R. L., SHEN, K., WYANT, G. A., 
PLOVANICH, M. E., YUAN, E. D., JONES, T. D., CHANTRANUPONG, L., 
COMB, W., WANG, T., BAR-PELED, L., ZONCU, R., STRAUB, C., KIM, 
C., PARK, J., SABATINI, B. L. & SABATINI, D. M. 2015. Metabolism. 
Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to 
mTORC1. Science, 347, 188-94. 
146 
 
WANG, X., ZHANG, X., DONG, X. P., SAMIE, M., LI, X., CHENG, X., 
GOSCHKA, A., SHEN, D., ZHOU, Y., HARLOW, J., ZHU, M. X., 
CLAPHAM, D. E., REN, D. & XU, H. 2012. TPC proteins are 
phosphoinositide- activated sodium-selective ion channels in endosomes 
and lysosomes. Cell, 151, 372-83. 
 
WATTS, C. 2012. The endosome-lysosome pathway and information generation 
in the immune system. Biochim Biophys Acta, 1824, 14-21. 
 
WEISIGER, R. A. & FRIDOVICH, I. 1973. Superoxide dismutase. Organelle 
specificity. J Biol Chem, 248, 3582-92. 
 
WEISS, F. H. A. J. 1934. The catalytic decomposition of hydrogen peroxide by 
iron salts. Royal Society. 
 
WONG, C. O., LI, R., MONTELL, C. & VENKATACHALAM, K. 2012. Drosophila 
TRPML is required for TORC1 activation. Curr Biol, 22, 1616-21. 
 
XIONG, J. & ZHU, M. X. 2016a. Regulation of lysosomal ion homeostasis by 
channels and transporters. Sci China Life Sci, 59, 777-91. 
 
XIONG, J. & ZHU, M. X. 2016b. Regulation of lysosomal ion homeostasis by 
channels and transporters. Science China. Life sciences, 59, 777-791. 
 
XU, H. & REN, D. 2015. Lysosomal Physiology. Annual Review of Physiology, 
77, 57-80. 
 
XU, J., TIAN, W., MA, X., GUO, J., SHI, Q., JIN, Y., XI, J. & XU, Z. 2011. The 
Molecular Mechanism Underlying Morphine-Induced Akt Activation: Roles 
of Protein Phosphatases and Reactive Oxygen Species. Cell Biochemistry 
and Biophysics, 61, 303-311. 
 
YOSHIMORI, T., YAMAMOTO, A., MORIYAMA, Y., FUTAI, M. & TASHIR, Y. 
1991. Bafilomycin AI, a Specific Inhibitor of Vacuolar-type H+-ATPase, 
Inhibits Acidification and Protein Degradation in Lysosomes of Cultured 
Cells. THE JOURNAL OF BIOLOGICAL CHEMISTRY 
. 
ZECCA, L., YOUDIM, M. B., RIEDERER, P., CONNOR, J. R. & CRICHTON, R. 
R. 2004. Iron, brain ageing and neurodegenerative disorders. Nat Rev 
Neurosci, 5, 863-73. 
 
ZHANG, X., CHENG, X., YU, L., YANG, J., CALVO, R., PATNAIK, S., HU, X., 
GAO, Q., YANG, M., LAWAS, M., DELLING, M., MARUGAN, J., 
FERRER, M. & XU, H. 2016. MCOLN1 is a ROS sensor in lysosomes that 
regulates autophagy. Nat Commun, 7, 12109. 
147 
 
ZHARKICH, I. L., NADEEV, A. D., TSITRIN, E. B., GONCHAROV, N. V. & 
AVDONIN, P. V. 2016. Suppression of Histamine-Induced Relaxation of 
Rat Aorta and Calcium Signaling in Endothelial Cells by Two-Pore 
Channel Blocker trans-NED19 and Hydrogen Peroxide. Izv Akad Nauk 




ATP Adenosine Triphosphate  
AF Auranofin 
BAF Bafilomycin A1 
CSA Cyclosporin A 
CQ Chloroquine 
DFO Deferoxamine 
DMEM Dulbecco’s Modified Eagle’s Medium 
EEA1 Early Endolysosomes 
FAC Ferric Ammonium Citrate 
Fe2+ Ferrous Iron 
Fe3+ Ferric Iron 
GPN Glycyl-l-Phenylalanine 2-Naphthylamide 
Gp120 Glycoprotein 120 
HAND HIV-Associated Neurocognitive Disorders 
HO Hydroxyl Radical 
H2O2 Hydrogen Peroxide 
149 
ISC Iron-Sulfur Clusters 
LAMP1 Late Endosomes/Lysosomes 
MFI Mean Fluorescent Intensity 
MnSOD Manganese Superoxide Dismutase 
MOR Morphine 
MPTP Mitochondrial Permeability Transition Pores 
NAADP Nicotinic Acid Adenine Dinucleotide Phosphate 
O2 Oxygen 
O2- Superoxide 
PI Propidium Iodide 
RDA Rhodamine B 4-[(2,2'-bipyridin-4-yl)Aminocarbonyl]Benzyl 
Ester 
ROS Reactive Oxygen Species 
SOD Superoxide Dismutase 
TPC Two-Pore Channls 
TAT Trans-activator of Transcription Protein 
TRPML Transient Receptor Potential Mucolipin 
U87MG Glioblastoma 
 
